# Quarterly Financial Information - ITR

## Diagnósticos da América S.A.

September 30, 2013

# Contents

## Company data / Capital Composition

| Number of shares (Units) | Current quarter 9/30/2013 |
|---|---|
| Paid-in capital | |
| Common shares | 311,803,015 |
| Preferred shares | 0 |
| Total | 311,803,015 |
| Treasury shares | |
| Common shares | 1,159,035 |
| Preferred shares | 0 |
| Total | 1,159,035 |

## Company Data / Cash Earnings

| Event | Approval | Earnings | Initial Payment | Share | Class of Share | Earnings per share (Reais / Share) |
|---|---|---|---|---|---|---|
| Annual General Meeting | 4/22/2013 | Dividends | 6/20/2013 | Common | | 0.06600 |

# Individual Quarterly Financial Information / Statement of Financial Position - Assets

## (R$ thousand)

| Code | Description | Current year 9/30/2013 | Previous year 12/31/2012 |
|---|---|---|---|
| 1 | Total assets | 4,120,163 | 4,058,267 |
| 1.01 | Current assets | 734,622 | 663,079 |
| 1.01.01 | Cash and cash equivalents | 162,501 | 152,546 |
| 1.01.03 | Accounts receivable | 410,201 | 354,812 |
| 1.01.03.01 | Trade accounts receivable | 410,201 | 354,812 |
| 1.01.04 | Inventories | 39,188 | 39,460 |
| 1.01.06 | Taxes recoverable | 93,090 | 82,042 |
| 1.01.06.01 | Current taxes recoverable | 93,090 | 82,042 |
| 1.01.07 | Prepaid expenses | 1,044 | 789 |
| 1.01.08 | Other current assets | 28,598 | 33,430 |
| 1.01.08.03 | Other | 28,598 | 33,430 |
| 1.01.08.03.20 | Other receivables | 28,598 | 33,430 |
| 1.02 | Non-current assets | 3,385,541 | 3,395,188 |
| 1.02.01 | Long-term receivables | 130,502 | 154,430 |
| 1.02.01.01 | Marketable securities at fair value | 27,672 | 46,803 |
| 1.02.01.01.01 | Marketable securities | 27,672 | 46,803 |
| 1.02.01.07 | Prepaid expenses | 822 | 982 |
| 1.02.01.08 | Receivables from related parties | 10,000 | 15,500 |
| 1.02.01.08.02 | Receivables from subsidiaries | 10,000 | 15,500 |
| 1.02.01.09 | Other non-current assets | 92,008 | 91,145 |
| 1.02.01.09.04 | Judicial deposits | 91,980 | 91,117 |
| 1.02.01.09.05 | Other non-current assets | 28 | 28 |
| 1.02.02 | Investments | 430,239 | 401,915 |
| 1.02.02.01 | Equity interest | 429,613 | 401,554 |
| 1.02.02.01.02 | Investments in subsidiaries | 429,613 | 401,554 |
| 1.02.02.02 | Investment properties | 626 | 361 |
| 1.02.02.02.20 | Others | 626 | 361 |
| 1.02.03 | Property and equipment | 525,368 | 539,808 |
| 1.02.04 | Intangible assets | 2,299,432 | 2,299,035 |
| 1.02.04.01 | Intangible assets | 2,299,432 | 2,299,035 |

# Individual Quarterly Financial Information / Statement of Financial Position - Liabilities

## (R$ thousand)

| Code | Description | Current year 9/30/2013 | Previous year 12/31/2012 |
|---|---|---|---|
| 2 | Total liabilities | 4,120,163 | 4,058,267 |
| 2.01 | Current liabilities | 584,214 | 312,742 |
| 2.01.01 | Social security and labor liabilities | 94,067 | 59,409 |
| 2.01.02 | Trade accounts payable | 52,789 | 54,714 |
| 2.01.03 | Tax liabilities | 10,225 | 9,608 |
| 2.01.04 | Loans and financing | 342,976 | 91,325 |
| 2.01.04.01 | Loans and financing | 10,939 | 16,840 |
| 2.01.04.02 | Debentures | 332,037 | 74,485 |
| 2.01.05 | Other liabilities | 84,157 | 97,686 |
| 2.01.05.02 | Other | 84,157 | 97,686 |
| 2.01.05.02.01 | Dividends and interest on equity payable | 4 | 20,235 |
| 2.01.05.02.04 | Taxes in installments | 1,108 | 2,370 |
| 2.01.05.02.05 | Accounts payable for acquisition of subsidiaries | 1,668 | 1,598 |
| 2.01.05.02.06 | Capital deficiency of subsidiaries | 16,031 | 26,130 |
| 2.01.05.02.07 | Financial instruments | 126 | 763 |
| 2.01.05.02.08 | Other payables | 65,220 | 46,590 |
| 2.02 | Non-current liabilities | 834,151 | 1,138,715 |
| 2.02.01 | Loans and financing | 656,397 | 895,811 |
| 2.02.01.01 | Loans and financing | 4,292 | 11,312 |
| 2.02.01.02 | Debentures | 652,105 | 884,499 |
| 2.02.02 | Other liabilities | 49,502 | 68,440 |
| 2.02.02.02 | Other | 49,502 | 68,440 |
| 2.02.02.02.03 | Taxes in installments | 9,458 | 10,022 |
| 2.02.02.02.04 | Accounts payable for acquisition of subsidiaries | 36,467 | 57,002 |
| 2.02.02.02.05 | Financial instruments | 37 | 470 |
| 2.02.02.02.06 | Other payables | 3,540 | 946 |
| 2.02.03 | Deferred taxes | 75,977 | 45,538 |
| 2.02.03.01 | Deferred income and social contribution taxes | 75,977 | 45,538 |
| 2.02.04 | Provisions | 52,275 | 128,926 |
| 2.02.04.01 | Provisions for tax, civil and labor risks | 52,275 | 128,926 |
| 2.03 | Equity | 2,701,798 | 2,606,810 |
| 2.03.01 | Paid-in capital | 2,234,135 | 2,234,135 |
| 2.03.02 | Capital reserves | 48,837 | 48,171 |
| 2.03.02.02 | Special reserve for goodwill on merger | 65,427 | 65,427 |
| 2.03.02.04 | Granted options | 2,027 | 1,361 |
| 2.03.02.05 | Treasury shares | -18,617 | -18,617 |
| 2.03.04 | Revenue reserves | 323,135 | 322,933 |
| 2.03.04.01 | Legal reserve | 23,563 | 23,563 |
| 2.03.04.05 | Retained profit reserve | 299,572 | 299,101 |
| 2.03.04.08 | Additional proposed dividend | 0 | 269 |
| 2.03.05 | Retained earnings | 94,591 | 0 |
| 2.03.06 | Other comprehensive income | 1,100 | 1,571 |

## Individual Quarterly Financial Information financial Statements / Statement of Income

## (R$ thousand)

| Code | Description | Current quarter 7/1/2013 to 9/30/2013 | Accumulated current year 1/1/2013 to 9/30/2013 | Previous quarter 7/1/2012 to 9/30/2012 | Accumulated previous year 1/1/2012 to 9/30/2012 |
|---|---|---|---|---|---|
| 3.01 | Revenue from services rendered | 461,179 | 1,330,874 | 415,360 | 1,208,669 |
| 3.02 | Cost of services rendered | -312,440 | -916,410 | -288,834 | -821,804 |
| 3.03 | Gross Profit | 148,739 | 414,464 | 126,526 | 386,865 |
| 3.04 | Operating income/expenses | -78,035 | -238,871 | -68,416 | -197,711 |
| 3.04.02 | General and administrative expenses | -101,086 | -290,313 | -85,972 | -253,474 |
| 3.04.04 | Other operating income | 8,182 | 8,112 | 661 | 1,369 |
| 3.04.06 | Equity pickup | 14,869 | 43,330 | 16,895 | 54,394 |
| 3.05 | Income before financial income/expenses and taxes | 70,704 | 175,593 | 58,110 | 189,154 |
| 3.06 | Financial income/expenses | -20,927 | -50,562 | -24,930 | -83,154 |
| 3.06.01 | Financial income | 36,887 | 66,083 | 6,776 | 25,654 |
| 3.06.02 | Financial expenses | -57,814 | -116,645 | -31,706 | -108,808 |
| 3.07 | Income before income and social contribution taxes | 49,777 | 125,031 | 33,180 | 106,000 |
| 3.08 | Income and social contribution taxes | -13,867 | -30,440 | -6,235 | -19,404 |
| 3.08.02 | Deferred | -13,867 | -30,440 | -6,235 | -19,404 |
| 3.09 | Net income from continuing operations | 35,910 | 94,591 | 26,945 | 86,596 |
| 3.11 | Net income for the period | 35,910 | 94,591 | 26,945 | 86,596 |
| 3.99 | Earnings per share (reais/share) | | | | |
| 3.99.01 | Basic earnings per share | | | | |
| 3.99.01.01 | Common shares | 0.11560 | 0.30450 | 0.08674 | 0.27876 |
| 3.99.02 | Diluted earnings per share | | | | |
| 3.99.02.01 | Common shares | 0.11548 | 0.30419 | 0.08672 | 0.27870 |

## Individual Quarterly Financial Information / Statement of Comprehensive Income

## (R$ thousand)

| Code | Description | Current quarter 7/1/2013 to 9/30/2013 | Accumulated current year 1/1/2013 to 9/30/2013 | Previous quarter 7/1/2012 to 9/30/2012 | Accumulated previous year 1/1/2012 to 9/30/2012 |
|---|---|---|---|---|---|
| 4.01 | Net income for the period | 35,910 | 94,591 | 26,945 | 86,596 |
| 4.03 | Comprehensive income for the period | 35,910 | 94,591 | 26,945 | 86,596 |

# Individual Quarterly Financial Information / Statement of Cash Flows

# (R$ thousand)

| Code | Description | Accumulated current year 1/1/2013 to 9/30/2013 | Accumulated previous year 1/1/2012 to 9/30/2012 |
|---|---|---|---|
| 6.01 | Net cash from operating activities | 150,097 | 211,503 |
| 6.01.01 | Cash from operations | 229,834 | 237,913 |
| 6.01.01.01 | Net income for the period | 94,591 | 86,596 |
| 6.01.01.02 | Depreciation and amortization | 95,236 | 82,270 |
| 6.01.01.03 | Restatement of contingencies | 12,498 | 10,701 |
| 6.01.01.04 | Deferred taxes | 30,440 | 19,404 |
| 6.01.01.05 | Restatement of interest and exchange variation on loans | 64,067 | 70,244 |
| 6.01.01.06 | Gain on sale of property and equipment | 9,156 | 4,684 |
| 6.01.01.07 | Stock-option plan granted | 667 | 895 |
| 6.01.01.08 | Equity pickup | -43,330 | -54,394 |
| 6.01.01.09 | Loss on Capital Equity Interest | 279 | 343 |
| 6.01.01.10 | Provision for disallowance and default | -33,770 | 17,170 |
| 6.01.02 | Changes in assets and liabilities | -79,737 | -26,410 |
| 6.01.02.01 | Increase in trade accounts receivable and other receivables | -21,619 | -46,077 |
| 6.01.02.02 | Decrease in inventories | 272 | 16,605 |
| 6.01.02.03 | Decrease in other current assets | -11,031 | 37,053 |
| 6.01.02.04 | Increase in other non-current assets | 8,166 | -13,254 |
| 6.01.02.05 | Increase (decrease) in trade accounts payable | -1,925 | -6,445 |
| 6.01.02.06 | Decrease in accounts payable and provisions | -53,600 | -14,292 |
| 6.02 | Net cash used in investing activities | -66,743 | -103,732 |
| 6.02.01 | Additions to property and equipment | -68,446 | -137,982 |
| 6.02.02 | Additions to intangible assets | -23,251 | -15,402 |
| 6.02.06 | Capital increase in subsidiaries | -22,485 | -49 |
| 6.02.08 | Interest on equity received | 47,439 | 49,701 |
| 6.03 | Net cash used in financing activities | -73,399 | -208,301 |
| 6.03.02 | Payment of loans | -13,233 | -116,822 |
| 6.03.07 | Dividends and interest on equity reserve paid | -20,500 | -36,401 |
| 6.03.08 | Interest paid | -39,666 | -55,078 |
| 6.05 | Increase (decrease) in cash and cash equivalents | 9,955 | -100,530 |
| 6.05.01 | At beginning of period | 152,546 | 156,978 |
| 6.05.02 | At end of period | 162,501 | 56,448 |

# Individual Quarterly Financial Information / Statement of Changes in Equity – 1/1/2013 to 9/30/2013

## (R$ thousand)

| Code | Description | Paid-in Capital | Capital Reserve – Granted options and treasury shares | Income reserve | Retained earnings | Other comprehensive income | Equity |
|---|---|---|---|---|---|---|---|
| 5.01 | Opening balances | 2,234,135 | 48,171 | 322,933 | 0 | 1,571 | 2,606,810 |
| 5.03 | Adjusted opening balances | 2,234,135 | 48,171 | 322,933 | 0 | 1,571 | 2,606,810 |
| 5.04 | Transactions with shareholders | 0 | 666 | 0 | 0 | 0 | 666 |
| 5.04.03 | Granted options | 0 | 666 | 0 | 0 | 0 | 666 |
| 5.05 | Other comprehensive income | 0 | 0 | 0 | 94,591 | 0 | 94,591 |
| 5.05.01 | Net Income for the period | 0 | 0 | 0 | 94,591 | 0 | 94,591 |
| 5.06 | Internal changes in shareholders' equity | 0 | 0 | 202 | 0 | -471 | -269 |
| 5.06.04 | Depreciation of deemed cost | 0 | 0 | 471 | 0 | -471 | 0 |
| 5.06.05 | Additional dividends Paid | 0 | 0 | -269 | 0 | 0 | -269 |
| 5.07 | Closing balances | 2,234,135 | 48,837 | 323,135 | 94,591 | 1,100 | 2,701,798 |

# Individual Quarterly Financial Information / Statement of Changes in Equity - 1/1/2012 to 9/30/2012

## (R$ thousand)

| Code | Description | Paid-in Capital | Capital Reserve - Granted options and treasury shares | Income reserve | Retained earnings | Other comprehensive income | Equity |
|---|---|---|---|---|---|---|---|
| 5.01 | Opening balances | 2,234,135 | 46,810 | 259,204 | 0 | 2,199 | 2,542,348 |
| 5.03 | Adjusted opening balances | 2,234,135 | 46,810 | 259,204 | 0 | 2,199 | 2,542,348 |
| 5.04 | Transactions with shareholders | 0 | 895 | -1,857 | 0 | 0 | -962 |
| 5.04.03 | Granted options | 0 | 895 | 0 | 0 | 0 | 895 |
| 5.04.06 | Dividends | 0 | 0 | -1,857 | 0 | 0 | -1,857 |
| 5.05 | Other comprehensive income | 0 | 0 | 0 | 86,596 | 0 | 86,596 |
| 5.05.01 | Net income for the period | 0 | 0 | 0 | 86,596 | 0 | 86,596 |
| 5.06 | Internal changes in shareholders' equity | 0 | 0 | 471 | 0 | -471 | 0 |
| 5.06.04 | Depreciation of deemed cost | 0 | 0 | 471 | 0 | -471 | 0 |
| 5.07 | Closing balances | 2,234,135 | 47,705 | 257,818 | 86,596 | 1,728 | 2,627,982 |

# Individual Quarterly Financial Information / Statement of Value Added

## (R$ thousand)

| Code | Description | Accumulated current year 1/1/2013 to 9/30/2013 | Accumulated previous year 1/1/2012 to 9/30/2012 |
|---|---|---|---|
| 7.01 | Revenue | 1,479,707 | 1,340,607 |
| 7.01.01 | Sales of goods, products and services | 1,471,693 | 1,339,473 |
| 7.01.02 | Other revenue | 8,112 | 1,369 |
| 7.01.04 | (Reversal of) allowance for doubtful accounts | -98 | -235 |
| 7.02 | Inputs acquired from third parties | -695,624 | -636,751 |
| 7.02.01 | Cost of products, goods and services sold | -504,108 | -453,502 |
| 7.02.02 | Materials, energy, third-party services and other | -191,516 | -181,581 |
| 7.02.03 | Loss (Recovery) of assets | 0 | -1,668 |
| 7.03 | Gross value added | 784,083 | 703,856 |
| 7.04 | Retentions | -95,236 | -82,270 |
| 7.04.01 | Depreciation, amortization and depletion | -95,236 | -82,270 |
| 7.05 | Net value added produced | 688,847 | 621,586 |
| 7.06 | Transferred value added received | 109,413 | 80,048 |
| 7.06.01 | Equity pickup | 43,330 | 54,394 |
| 7.06.02 | Financial income | 66,083 | 25,654 |
| 7.07 | Total value added to be distributed | 798,260 | 701,634 |
| 7.08 | Distribution of value added | 798,260 | 701,634 |
| 7.08.01 | Personnel | 332,708 | 289,105 |
| 7.08.02 | Taxes, fees and contributions | 178,210 | 154,087 |
| 7.08.03 | Debt remuneration | 192,751 | 171,846 |
| 7.08.04 | Equity remuneration | 94,591 | 86,596 |
| 7.08.04.03 | Retained profits | 94,591 | 86,596 |

# Consolidated Quarterly Financial Information / Statement of Financial Position - Assets

## (R$ thousand)

| Code | Description | Current year 9/30/2013 | Previous year 12/31/2012 |
|---|---|---|---|
| 1 | Total assets | 4,351,510 | 4,272,175 |
| 1.01 | Current assets | 1,112,902 | 993,438 |
| 1.01.01 | Cash and cash equivalents | 222,760 | 228,519 |
| 1.01.02 | Marketable securities | 29,675 | 31,953 |
| 1.01.02.01 | Marketable securities at fair value | 29,675 | 31,953 |
| 1.01.02.01.01 | Securities for trading | 29,675 | 31,953 |
| 1.01.03 | Accounts receivable | 592,556 | 498,455 |
| 1.01.03.01 | Trade accounts receivable | 592,556 | 498,455 |
| 1.01.04 | Inventories | 57,536 | 61,442 |
| 1.01.06 | Taxes recoverable | 175,185 | 138,462 |
| 1.01.06.01 | Current taxes recoverable | 175,185 | 138,462 |
| 1.01.07 | Prepaid expenses | 1,159 | 979 |
| 1.01.08 | Other current assets | 34,031 | 33,628 |
| 1.01.08.03 | Other | 34,031 | 33,628 |
| 1.01.08.03.20 | Other receivables | 34,031 | 33,628 |
| 1.02 | Non-current assets | 3,238,608 | 3,278,737 |
| 1.02.01 | Long-term receivables | 198,338 | 214,305 |
| 1.02.01.01 | Marketable securities at fair value | 39,079 | 57,635 |
| 1.02.01.01.01 | Securities for trading | 39,079 | 57,635 |
| 1.02.01.06 | Deferred taxes | 59,178 | 57,002 |
| 1.02.01.06.01 | Deferred income and social contribution taxes | 59,178 | 57,002 |
| 1.02.01.07 | Prepaid expenses | 822 | 982 |
| 1.02.01.09 | Other non-current assets | 99,259 | 98,686 |
| 1.02.01.09.04 | Judicial deposits | 96,751 | 95,274 |
| 1.02.01.09.05 | Other non-current assets | 2,508 | 3,412 |
| 1.02.02 | Investments | 779 | 516 |
| 1.02.02.02 | Investment Properties | 779 | 516 |
| 1.02.02.02.01 | Other | 779 | 516 |
| 1.02.03 | Property and equipment | 692,917 | 716,474 |
| 1.02.04 | Intangible assets | 2,346,574 | 2,347,442 |
| 1.02.04.01 | Intangible assets | 2,346,574 | 2,347,442 |

# Consolidated Quarterly Financial Information / Statement of Financial Position - Liabilities

## (R$ thousand)

| Code | Description | Current year 9/30/2013 | Previous year 12/31/2012 |
|---|---|---|---|
| 2 | Total liabilities | 4,351,510 | 4,272,175 |
| 2.01 | Current liabilities | 763,190 | 400,966 |
| 2.01.01 | Social security and labor liabilities | 122,852 | 81,191 |
| 2.01.02 | Trade accounts payable | 78,562 | 84,429 |
| 2.01.03 | Tax liabilities | 44,654 | 30,335 |
| 2.01.04 | Loans and financing | 429,695 | 119,005 |
| 2.01.04.01 | Loans and financing | 97,658 | 44,520 |
| 2.01.04.02 | Debentures | 332,037 | 74,485 |
| 2.01.05 | Other liabilities | 87,427 | 86,006 |
| 2.01.05.02 | Other | 87,427 | 86,006 |
| 2.01.05.02.01 | Dividends and Interest equity payable | 4 | 20,235 |
| 2.01.05.02.04 | Taxes in installments | 4,757 | 4,820 |
| 2.01.05.02.05 | Accounts payable for acquisition of subsidiaries | 1,668 | 1,598 |
| 2.01.05.02.07 | Financial instruments | 126 | 763 |
| 2.01.05.02.20 | Other accounts payable | 80,872 | 58,590 |
| 2.02 | Non-current liabilities | 886,007 | 1,264,017 |
| 2.02.01 | Loans and financing | 679,438 | 987,376 |
| 2.02.01.01 | Loans and financing | 27,333 | 102,877 |
| 2.02.01.02 | Debentures | 652,105 | 884,499 |
| 2.02.02 | Other liabilities | 74,999 | 97,260 |
| 2.02.02.02 | Other | 74,999 | 97,260 |
| 2.02.02.02.03 | Taxes in installments | 23,549 | 28,010 |
| 2.02.02.02.04 | Accounts payable for acquisition of subsidiaries | 47,873 | 67,834 |
| 2.02.02.02.05 | Financial instruments | 37 | 470 |
| 2.02.02.02.20 | Other accounts payable | 3,540 | 946 |
| 2.02.03 | Deferred taxes | 75,977 | 47,130 |
| 2.02.03.01 | Deferred income and social contribution taxes | 75,977 | 47,130 |
| 2.02.04 | Provisions | 55,593 | 132,251 |
| 2.02.04.01 | Provisions for tax, civil and labor risks | 55,593 | 132,251 |
| 2.03 | Consolidated equity | 2,702,313 | 2,607,192 |
| 2.03.01 | Paid-in capital | 2,234,135 | 2,234,135 |
| 2.03.02 | Capital reserves | 48,837 | 48,171 |
| 2.03.02.02 | Special reserve for goodwill on merger | 65,427 | 65,427 |
| 2.03.02.04 | Granted options | 2,027 | 1,361 |
| 2.03.02.05 | Treasury Shares | -18,617 | -18,617 |
| 2.03.04 | Income reserves | 323,135 | 322,933 |
| 2.03.04.01 | Legal reserve | 23,563 | 23,563 |
| 2.03.04.05 | Retained income reserve | 299,572 | 299,101 |
| 2.03.04.08 | Additional proposed dividend | 0 | 269 |
| 2.03.05 | Retained Earnings | 94,591 | 0 |
| 2.03.06 | Other comprehensive income | 1,100 | 1,571 |
| 2.03.09 | Non-controlling interest | 515 | 382 |

# Consolidated Quarterly Financial Information / Statement of Income

## (R$ thousand)

| Code | Description | Current quarter 7/1/2013 to 9/30/2013 | Accumulated current year 1/1/2013 to 9/30/2013 | Previous quarter 7/1/2012 to 9/30/2012 | Accumulated previous year 1/1/2012 to 9/30/2012 |
|---|---|---|---|---|---|
| 3.01 | Revenue from products sold and/or services rendered | 646,171 | 1,859,091 | 588,430 | 1,716,742 |
| 3.02 | Cost of products sold and/or services rendered | -436,701 | -1,273,464 | -404,776 | -1,150,641 |
| 3.03 | Gross profit | 209,470 | 585,627 | 183,654 | 566,101 |
| 3.04 | Operating income/expenses | -125,047 | -370,860 | -117,821 | -342,748 |
| 3.04.02 | General and administrative expenses | -133,295 | -381,099 | -119,240 | -345,456 |
| 3.04.04 | Other operating income | 8,248 | 10,239 | 1,419 | 2,708 |
| 3.05 | Profit before financial income/expenses and taxes | 84,423 | 214,767 | 65,833 | 223,353 |
| 3.06 | Financial income/expenses | -27,347 | -66,441 | -25,475 | -91,545 |
| 3.06.01 | Financial income | 40,154 | 74,621 | 12,201 | 42,286 |
| 3.06.02 | Financial expenses | -67,501 | -141,062 | -37,676 | -133,831 |
| 3.07 | Income before income and social contribution taxes | 57,076 | 148,326 | 40,358 | 131,808 |
| 3.08 | Income and social contribution taxes | -21,084 | -53,602 | -13,594 | -45,481 |
| 3.08.01 | Current | -6,896 | -26,930 | -8,839 | -24,075 |
| 3.08.02 | Deferred | -14,188 | -26,672 | -4,755 | -21,406 |
| 3.09 | Net income from continuing operations | 35,992 | 94,724 | 26,764 | 86,327 |
| 3.11 | Consolidated net income for the period | 35,992 | 94,724 | 26,764 | 86,327 |
| 3.11.01 | Attributed to controlling shareholders | 35,910 | 94,591 | 26,945 | 86,596 |
| 3.11.02 | Attributed to non-controlling shareholders | 82 | 133 | -181 | -269 |
| 3.99 | Earnings per share (reais/share) | | | | |
| 3.99.01 | Basic earnings per share | | | | |
| 3.99.01.01 | Common shares | 0.11586 | 0.30493 | 0.08616 | 0.27790 |
| 3.99.02 | Diluted earnings per share | | | | |
| 3.99.02.01 | Common shares | 0.11574 | 0.30462 | 0.08614 | 0.27783 |

# Consolidated Quarterly Financial Information / Statement of Comprehensive Income

## (R$ thousand)

| Code | Description | Current quarter 7/1/2013 to 9/30/2013 | Accumulated current year 1/1/2013 to 9/30/2013 | Previous quarter 7/1/2012 to 9/30/2012 | Accumulated previous year 1/1/2012 to 9/30/2012 |
|---|---|---|---|---|---|
| 4.01 | Consolidated net income for the period | 35,992 | 94,724 | 26,764 | 86,327 |
| 4.03 | Consolidated other comprehensive income for the period | 35,992 | 94,724 | 26,764 | 86,327 |
| 4.03.01 | Attributed to controlling shareholders | 35,910 | 94,591 | 26,945 | 86,596 |
| 4.03.02 | Attributed to non-controlling shareholders | 82 | 133 | -181 | -269 |

# Consolidated Quarterly Financial Information / Statement of Cash Flows

## (R$ thousand)

| Code | Description | Accumulated current year 1/1/2013 to 9/30/2013 | Accumulated previous year 1/1/2012 to 9/30/2012 |
|---|---|---|---|
| 6.01 | Net cash from operating activities | 194,031 | 224,010 |
| 6.01.01 | Cash from operations | 305,803 | 338,769 |
| 6.01.01.01 | Net income for the period | 94,724 | 86,327 |
| 6.01.01.02 | Depreciation and amortization | 115,863 | 108,917 |
| 6.01.01.03 | Restatement of contingencies | 12,498 | 10,922 |
| 6.01.01.04 | Deferred taxes | 26,672 | 21,406 |
| 6.01.01.05 | Restatement of interest and exchange variation on loans | 79,281 | 83,576 |
| 6.01.01.06 | Gain on sale of property and equipment | 9,359 | 5,800 |
| 6.01.01.07 | Non-controlling interest | 0 | -187 |
| 6.01.01.08 | Stock-option plan granted | 667 | 895 |
| 6.01.01.10 | Provision for disallowance and default | -31,935 | 21,113 |
| 6.01.01.12 | Interest and exchange variation on marketable securities | -1,326 | 0 |
| 6.01.02 | Changes in assets and liabilities | -91,676 | -98,715 |
| 6.01.02.01 | Increase in accounts receivable and other receivables | -62,166 | -71,136 |
| 6.01.02.02 | Decrease in inventories | 3,906 | 17,755 |
| 6.01.02.03 | Increase in other current assets | -33,593 | -43,194 |
| 6.01.02.04 | Increase in other non-current assets | 17,786 | -26,256 |
| 6.01.02.05 | Increase (decrease) in trade accounts payable | -5,867 | -2,279 |
| 6.01.02.06 | Increase in accounts payable and provisions | -11,742 | 26,395 |
| 6.01.03 | Other | -20,096 | -16,044 |
| 6.01.03.02 | Income and social contribution taxes paid | -20,096 | -16,044 |
| 6.02 | Net cash used in investing activities | -101,691 | -180,425 |
| 6.02.01 | Additions to property and equipment | -78,036 | -164,474 |
| 6.02.02 | Additions to intangible assets | -23,655 | -15,951 |
| 6.03 | Net cash used in financing activities | -98,099 | -185,140 |
| 6.03.01 | Loans granted | 71,377 | 45,081 |
| 6.03.02 | Payment of loans | -101,934 | -132,995 |
| 6.03.06 | Dividends and interest on equity reserve paid | -20,500 | -36,401 |
| 6.03.07 | Interest paid | -47,042 | -60,825 |
| 6.05 | Decrease in cash and cash equivalents | -5,759 | -141,555 |
| 6.05.01 | At beginning of period | 228,519 | 249,945 |
| 6.05.02 | At end of period | 222,760 | 108,390 |

# Consolidated Quarterly Financial Information / Statement of Changes in Equity - 1/1/2013 to 9/30/2013

## (R$ thousand)

| Code | Description | Paid-in Capital | Capital Reserve – Granted options and treasury shares | Income reserve | Retained earnings | Other comprehensive income | Equity | Non-controlling interest | Consolidated Equity |
|---|---|---|---|---|---|---|---|---|---|
| 5.01 | Opening balances | 2,234,135 | 48,171 | 322,933 | 0 | 1,571 | 2,606,810 | 382 | 2,607,192 |
| 5.03 | Adjusted opening balances | 2,234,135 | 48,171 | 322,933 | 0 | 1,571 | 2,606,810 | 382 | 2,607,192 |
| 5.04 | Transaction with shareholders | 0 | 666 | 0 | 0 | 0 | 666 | 0 | 666 |
| 5.04.03 | Granted options | 0 | 666 | 0 | 0 | 0 | 666 | 0 | 666 |
| 5.05 | Total comprehensive income | 0 | 0 | 0 | 94,591 | 0 | 94,591 | 133 | 94,724 |
| 5.05.01 | Net income for the period | 0 | 0 | 0 | 94,591 | 0 | 94,591 | 133 | 94,724 |
| 5.06 | Internal changes in equity | 0 | 0 | 202 | 0 | -471 | -269 | 0 | -269 |
| 5.06.04 | Depreciation of deemed cost | 0 | 0 | 471 | 0 | -471 | 0 | 0 | 0 |
| 5.06.05 | Additional dividends paid | 0 | 0 | -269 | 0 | 0 | -269 | 0 | -269 |
| 5.07 | Closing balances | 2,234,135 | 48,837 | 323,135 | 94,591 | 1,100 | 2,701,798 | 515 | 2,702,313 |

# Consolidated Quarterly Financial Information / Statement of Changes in Equity - 1/1/2012 to 9/30/2012

## (R$ thousand)

| Code | Description | Paid-in Capital | Capital Reserve –Granted options and treasury shares | Income reserve | Retained Earnings | Other comprehensive income | Equity | Non-controlling interest | Consolidated equity |
|---|---|---|---|---|---|---|---|---|---|
| 5.01 | Opening balances | 2,234,135 | 46,810 | 259,204 | 0 | 2,199 | 2,542,348 | -328 | 2,542,020 |
| 5.03 | Adjusted opening balances | 2,234,135 | 46,810 | 259,204 | 0 | 2,199 | 2,542,348 | -328 | 2,542,020 |
| 5.04 | Transaction with shareholders | 0 | 895 | -1,857 | 0 | 0 | -962 | 0 | -962 |
| 5.04.03 | Granted Options | 0 | 895 | 0 | 0 | 0 | 895 | 0 | 895 |
| 5.04.06 | Dividends | 0 | 0 | -1,857 | 0 | 0 | -1,857 | 0 | -1,857 |
| 5.05 | Total comprehensive income | 0 | 0 | 0 | 86,596 | 0 | 86,596 | -456 | 86,140 |
| 5.05.01 | Net income for the period | 0 | 0 | 0 | 86,596 | 0 | 86,596 | -269 | 86,327 |
| 5.05.02 | Other comprehensive income | 0 | 0 | 0 | 0 | 0 | 0 | -187 | -187 |
| 5.05.02.06 | Participation of non-controlling | 0 | 0 | 0 | 0 | 0 | 0 | -187 | -187 |
| 5.06 | Internal changes in shareholders' equity | 0 | 0 | 471 | 0 | -471 | 0 | 0 | 0 |
| 5.06.04 | Depreciation of deemed cost | 0 | 0 | 471 | 0 | -471 | 0 | 0 | 0 |
| 5.07 | Closing balances | 2,234,135 | 47,705 | 257,818 | 86,596 | 1,728 | 2,627,982 | -784 | 2,627,198 |

# Consolidated Quarterly Financial Information / Statement of Value Added

## (R$ thousand)

| Code | Description | Accumulated current year 1/1/2013 to 9/30/2013 | Accumulated previous year 1/1/2012 to 9/30/2012 |
|---|---|---|---|
| 7.01 | Revenue | 2,065,756 | 1,888,056 |
| 7.01.01 | Sale of goods, products and services | 2,055,677 | 1,885,727 |
| 7.01.02 | Other revenue | 10,239 | 2,708 |
| 7.01.04 | Reversal of allowance for doubtful accounts | -160 | -379 |
| 7.02 | Inputs acquired from third parties | -981,744 | -874,818 |
| 7.02.01 | Cost of products, goods and services sold | -711,741 | -632,506 |
| 7.02.02 | Materials, energy, third-party services and others | -270,003 | -240,644 |
| 7.02.03 | Loss (Recovery) of assets | 0 | -1,668 |
| 7.03 | Gross value added | 1,084,012 | 1,013,238 |
| 7.04 | Retentions | -115,863 | -108,917 |
| 7.04.01 | Depreciation, amortization and depletion | -115,863 | -108,917 |
| 7.05 | Net value added produced | 968,149 | 904,321 |
| 7.06 | Transferred value added received | 74,621 | 42,286 |
| 7.06.02 | Financial income | 74,621 | 42,286 |
| 7.07 | Total value added to be distributed | 1,042,770 | 946,607 |
| 7.08 | Distribution of value added | 1,042,770 | 946,607 |
| 7.08.01 | Personnel | 455,484 | 410,149 |
| 7.08.02 | Taxes, fees and contributions | 259,056 | 238,212 |
| 7.08.03 | Debt remuneration | 233,506 | 211,919 |
| 7.08.04 | Equity remuneration | 94,724 | 86,327 |
| 7.08.04.03 | Retained profits for the periods | 94,591 | 86,327 |
| 7.08.04.04 | Non-controlling interest | 133 | -269 |

## Comments on the Company's Performance

**Dear Shareholders,**

The third quarter of 2013 was marked by the change in the Company's growth level. Despite the signs of slow-down in the Brazilian economy, with the decrease in job creation, we managed to expand all business lines, evidence that the initiatives we took in 2012 were effective. For the first time in our history, we achieved revenue greater than R$ 700 million in this quarter. We set a new record in processing clinical analysis tests.

We remain focused in ensuring a new rhythm to our organic growth, in strengthening all business segments wherein we operate, in improving the quality of our service, in reinforcing our know-how and technical quality, in addition to intensifying the alignment of our people with DASA Culture, and reducing employee turnover. We managed to gradually and constantly improve our margins. We continued to work on the improvement of our internal processes and the Company is progressing in its goal of being recognized worldwide for its quality and efficiency in medical diagnosis, providing services to all social classes and compensating its shareholders.

### Gross operating revenue

The consolidated gross revenue of DASA for third quarter of 2013 reached R$ 716.7 million, i.e. a 9.8% growth in comparison with 3Q12, which is mainly a consequence of the full-fledged development of the projects implemented throughout 2012, as well as of the expansion of the service agenda and of a more favorable calendar. In this nine-month period of 2013, gross revenue was R$ 2,055.7 million, and 9.0% growth when compared with the same period in 2012, when we reached R$ 1,885.7 million.

An analysis of DASA's gross revenue by service line shows that the Lab-to-lab market achieved the best performance in the quarter, with a revenue of R$ 76.5 million and a 19.1% growth when compared with 3Q12, i.e. 10.7% of total revenue of DASA. In this nine-month period of 2013, the revenue totaled R$ 214.6 million, increasing 16.1% when compared with the same period in 2012, and reaching 10.4% of the Company's total revenue.

The Outpatient clinic market recorded revenue of R$ 520.9 million, 8.4% higher than 3Q12, and representing 72.7% of DASA's total revenue. In this nine-month period of 2013, the revenue totaled R$ 1,499.1 million, a 7.9% growth when compared with the same period in 2012, and 72.9% of the Company total revenue.

The Hospital market recorded revenue of R$ 69.2 million, 16.0% higher than 3Q13, and which stands for 9.7% of DASA's total revenue. In this nine-month period of 2013, the revenue totaled R$ 200.8 million, increasing 14.9% when compared with the same period in 2012, and reaching 9.8% of the Company's total revenue.

The Public market recorded revenue of R$ 50.2 million, i.e. a 4.4% increase in 3Q13, and 7% of DASA's total revenue. In this nine month period of 2013, revenue totaled R$ 141.2 million, a 3.5% growth when compared with the same period in 2012, or 6.9% of the Company's total revenue.

### Costs and Gross Profit

In 3Q13, the cost of services totaled R$ 436.7 million, which is equivalent to 67.6% of net revenue, a 7.9% increase when compared with the costs incurred in 3Q12. In 3Q13, gross profit totaled R$ 209.5 million, an increase of 14.1% when compared with the same period in the previous year. In this nine-month period of 2013, service costs totaled R$ 1,273.5 million, which is equivalent to 68.5% of net revenue, an increase of 10.7% in comparison with the same period in the previous year. Gross profit amounted to R$ 585.6 million, a decrease of 3.4% when compared with the same period in the previous year.

## Comments on the Company's Performance

## Operating expenses

Operating expenses totaled R$ 125.0 million in 3Q13, accounting for 19.4% of net income. In relation to 3Q12, there was a 6.1% increase, which accounted for 20.0% of the net income for that quarter. In this nine-month period of 2013, operating expenses totaled R$ 370.9 million, which is equivalent to 20.0% of net revenue, an increase of 8.2% in comparison with the same period in the previous year.

### EBITDA

In 3Q13, we reached an EBITDA of R$ 120.7 million, an 11.3% increase in relation to the R$ 108.5 million recorded in the same period in the previous year. In this quarter, we had a margin of 18.7%, compared with the margin of 18.4% in 3Q12. In this nine-month period of 2013, we achieved an EBITDA of R$ 330.6 million, a 1.0% decrease in relation to the R$ 333.8 million recorded in the same period of the previous year. We remain committed to integrating acquisitions, to optimizing production and administrative areas; and to a constant decrease in costs through a management focused on delivering solid results and creating sustainable value to shareholders in the future. The breakdown of the EBITDA calculation is described below:

| *In R$ million* | *3Q13* | *3Q12* | Δ% | *YTD 2013* | *YTD 2012* | Δ% |
|---|---|---|---|---|---|---|
| **Net income for the period** | **36.0** | **26.8** | **34.5%** | **94.7** | **86.3** | **9.7%** |
| (+) Income and social contribution taxes | 21.1 | 13.6 | 55.1% | 53.6 | 45.5 | 17.9% |
| (+) Net financial income | 27.3 | 25.1 | 7.3% | 66.4 | 91.5 | -27.9% |
| (+)Depreciation and amortization | 36.3 | 42.6 | -14.9% | 115.8 | 110.4 | 4.9% |
| **Ebitda** | **120.7** | **108.5** | **11.3%** | **330.6** | **333.8** | **-1.0%** |
| **Ebitda Margin (%)** | **18.7%** | **18,4%** | **0.3 p.p.** | **17,8%** | **19.4%** | **-1.6 p.p.** |

| *EBITIDA – Last twelve months* | YTD 3Q13 | Fourth Quarter 2012 | Last Twelve Months |
|---|---|---|---|
| Result before income and social contribution taxes | 1 48,3 | (0,5) | 147,8 |
| Depreciation, amortization (Cust) | 7 5,0 | 27,8 | 102,8 |
| Depreciação e Amortization (expenses) | 4 0,9 | 24,1 | 6 4,9 |
| Expenses (Revenue) net financial | 6 6,4 | 22,1 | 8 8,6 |
| EBITDA (LAJIDA) | 3 30,6 | 73,5 | 404,1 |

In 3Q13, R$ 27.3 million were recorded in net financial expenses against the R$ 25.5 million recorded in 3Q12. . The increase was mainly due to the exercise of buyback of shares from the remaining bonds, related to the payment of the option and write-off of prepaid expenses in the amount of R$5.5 million, and by the non-recurrent gains arising out of special tax installment payment (PEP) of State value-added tax (ICMS/SP) in the amount of R$ 2.7 million. In this nine-month period of 2013, R$ 66.4 million were recorded in net financial expenses, versus the R$ 91.5 million recorded for the same period in 2012 and the gain of PEP of ICMS/SP reached R$12.0 million in the year.

### Taxes

Taxes totaled R$ 21.1 million in this quarter, compared with R$ 13.6 million recorded in the third quarter of the previous year. In this nine-month period of 2013, taxes accumulated R$ 53.6 million, versus the R$ 45.5 million for the same period in the prior year.

## Comments on the Company's Performance

### Net income

In this quarter, net income amounted to R$ 36.0 million, 34.5% higher than the profit of R$ 26.8 million reported for the same period in 2012. In this nine-month period of 2013, net income was R$ 94.7 million, against the R$ 86.3 million recorded for the same period in the previous year 9.7% growth.

### Cash and marketable securities

We have ended this quarter recording a cash position and highly liquid marketable securities in the amount of R$ 252.4 million, which will be used to ensure the expansion and modernization of existing units; launch new units and replace imaging equipment; in addition to higher investments to improve quality and payment of dividends.

### CAPEX

CAPEX in 3Q13 achieved the net amount of R$ 31.4 million. From January to September 2013, CAPEX totaled R$ 101.7 million. This year's CAPEX of the remaining amount will be primarily allocated to: (i) implementation and development of production and service systems, as well as renewal of the technological assets, (ii) maintenance and expansion of the existing service units and construction of new units, (iii) purchase of imaging equipment.

### Indebtedness

DASA's net debt amounted to R$ 856.9 million in 3Q13. From the gross debt, 61.3% are long-term debts and 7.4% are debts in foreign currency. Indebtedness in foreign currency is mainly related to equipment financing and bank loan. Indebtedness in local currency refers primarily to debentures and leases.

### Material events for the quarter

***Request to resign from the position of Vice President and CFO and election of the Company's CFO***

The Board of Directors' meeting of September 13, 2013, held at 6pm, approved the resignation of Mrs. Cynthia May Hobbs Pinho from the position of Vice President and CFO, the mandate of which was exercised up to October 31, 2013. Mr. Paulo Bokel Catta-Preta was then elected as the acting CFO, cumulatively to the position of Investor Relations' Officer, duly elected in the Board of Directors' meeting held on April 22, 2012

***Issuance of Simple Debentures in a Single series***

On September 13, 2013, the Company communicated its shareholders and the market in general that its Board of Directors approved, on that date, the Company's forth issuance of up to 45,000 unsecured debentures in a single series not convertible into shares, with par value of R$10,000.00, totaling R$450,000,000.00 ("Debentures"), for public distribution with restrict placement efforts under CVM Ruling No. 476, of January 16, 2009, and amendments thereto.

***Administrative Council for Economic Defense (CADE)'s Approval – Previlab***

On September 6, 2013, the Company communicated to the market that CADE approved, during the 27th ordinary trial held on 08/28/2013, the acquisition of Previlab Análises Clínicas Ltda. by DASA (object of the application to carry joint operations No.08012.007541/2011-01), determined solely by the geographic extent limitation of the non-competition clause agreed upon by selling parties.

## Comments on the Company's Performance

***Buyback of Senior Notes***

On September 3, 2013, the Company communicated to the market the exercise of its right to acquire notes issued by its wholly-owned subsidiary, Dasa Finance Corporation, maturing in 2018 (8.75% Senior Notes due 2018) remaining from the acquisition announced on November 11, 2010 and concluded on December 16, 2010. With the acquisition, the Company informs there are no remaining Notes to be acquired.

The payment of amounts due to holders of Notes, who joined the acquisition offer, was made on August 30, 2013 and included the 4.875% premium as the deed of issue.

***São Paulo State Installment Payment Program***

The São Paulo State Decree No. 58811/12 created a special State VAT (ICMS) installment payment program ("PEP of ICMS/SP"), in which companies may enroll until August 31, 2013, and that established the elimination of up to 75% of fines and of up to 50% of interest related to ICMS debts, either incorporated or not, including those deemed as federal enforceable debt, whether executed or not, and referring to tax triggering events occurring until July 31, 2012. Debts subject to tax delinquency notice and imposition of fine (AIIM), and which are not federal enforceable debts, are entitled to additional fine deductions.

Given these favorable conditions, the Company decided to use the benefits offered by the PEP of ICMS/SP and joined the program in May 2013, which includes the ICMS debts on direct import of equipment and input carried out between 2007 and 2011, which have not been object of a tax delinquency notice yet, but are an object of a writ of mandamus issued by the São Paulo State Court. The payment in cash was made on May 22 and June 5, 2013, totaling R$ 39,398, as shown in the table below:

**Mandamus issued Nº 0046827-27.2011.8.26.0053**

| ICMS debits (Not reductions) | Reductions of PEP | Debits after PEP reductions | Existent provision | Profit obtained |
|---|---|---|---|---|
| 55,286 | (15,888) | 39,398 | 48,726 | (9,328) |

Consequently, considering that there was a previously set-up provision for contingencies for the referred to debts in the amount of R$ 48,726, final gains arising out of PEP was R$ 9,328. This amount was recognized in the financial income for the period.

Considering that the Company decided to pay in cash, there are no longer amounts recorded under liabilities in connection with the special installment payment program related to non-notified ICMS debts on import

On August 23, 2013, the Company also chose to include in PEP part of State VAT (ICMS)-import debts subject to Tax Delinquency Notice – AIIM No.3091324-8, of April 30, 2008. The aforesaid AIIM has ICMS debts levied on direct imports and international leases. The Company chose to include only debts related to direct imports for purposes of PEP, thus lease debts still remain subject to administrative procedure discussion.

The settlement in cash was made on September 3, 2013 in the amount of R$ 30,104, as under:.

**AIIM Nº 3.091.324-0**

| ICMS debits (Not reductions) | Reductions of PEP | Debits after PEP reduction | Existent provision | Profit obtained |
|---|---|---|---|---|
| 57,451 | (27,348) | 30,104 | 32,788 | (2,684) |

## Comments on the Company's Performance

Accordingly, considering the provision for contingencies previously set up for debts related to AIIM No.3.091.324-0 in the amount of R$32,788, the final gain obtained in joining the PEP program totaled R$2,684, which was recognized in the income statement for the period.

After the Company opted for the cash payment, there were no longer amounts recorded under liabilities related to special installment payment made for ICMS debts on direct imports contained in the AIIM No.3.091.324-0.

The legal deadline to join PEP ended on August 31, 2013, the table below summarizes the total amounts subject to Company:

**TOTAL**

| ICMS Debits (Not reductions) | Reductions of PEP | Debits after PEP reductions | Existent provision | Profit obtained |
|---|---|---|---|---|
| **112,737** | **(43,236)** | **69,502** | **81,514** | **(12,012)** |

To sum up, total amounts joined to PEP by the Company decreased the provision for contingencies, generating a gain of R$ 12,012, which was recognized in the income statement for the period. The remaining balance as at September 30, 2013 is amounted to R$81,514.

In December 2011, The Company decided to make judicial deposits in the amount of R$ 46,068, being R$ 53,609 at September 30, 2013 (R$ 51,642 at December 31, 2012) concerning ICMS amounts collected on direct imports of inputs and equipment cleared through customs in the state of São Paulo, not subject to tax notice, claiming the right to settle the tax by voluntary payment, not subject to fine and with interest reduction, maintaining the calculation criteria of amounts for provision for losses. The lower court decision was favorable to the Company in the sense of recognizing the arguments presented for the collection of interest, however it reject the claim presented by the Company related to the fine. Because the Company joined the PEP program, which covered all tax debts guaranteed by such deposit, it requested a court assessment.

At September 30, 2013, the provision for import carried out since January 1, 2003 is R$ 16.421 (R$ 96,155 at December 31, 2012) in Company and consolidated

**Significant subsequent events**

***<u>Ending of public offering of fourth issuance of Debentures</u>***

On October 17, 2013, the Company communicated its shareholders and the market in general the ending of the Public Distribution with Restrict Placement Efforts of DASA's fourth issue of Unsecured Debentures Not Convertible into Shares. A total of 45,000 debentures were subscribed, with a five-year term as from the issue date, therefore maturing on October 15, 2018, totaling R$ 450,000,000.00.

The debentures have clauses determining maximum indebtedness and leverage levels, which are calculated according to (i) net debt / EBITDA, which should be lower than or equal to 3.0, and (ii) EBITDA/ financial income, which should be higher than or equal to 2.0.

**Outlook for 2013**

In 2013, DASA is reinforcing its medical relationship program with an expansion of over 50% in the these activities, compared with the prior year.

## Comments on the Company's Performance

Furthermore, DASA had 53 projects approved at the 2013 AACC (American Association for Clinical Chemistry), which corresponds to 61% of the Brazilian studies submitted in that conference, which is the main Clinical Analysis conference in the world. One of the projects was particularly recognized and was awarded in the conference organized by the NACB (National Academy of Clinical Biochemistry). More than 200 medical events had already been organized, with highlights to Second International Diagnostic Medicine Conference, to be held under our Delboni Auriemo brand in October. The meeting has classes with six medical specialties and lectures from internationally renowned speakers to a public of more than 600 professionals in the health care area.

All investments in modernization of the existing units, opening of new units, replacement of imaging equipment together with increased investments in quality improvement will ultimately provide for an environment of growth. We continue to unify the Company's systems that will simplify our management process.

This call-center operation already presents improvement indicators, and we remain focused on maximizing imaging equipment agenda and increasing the productivity of our Patient Service Center.

**Arbitration clause**

Any arbitration is to be held at the Market Arbitration Chamber, in accordance with the arbitration clause set forth in the Company's charter.

**Projections and non-accounting data**

The statements herein related to business prospects, projections on operating and financial results, and those related to the Company's growth prospects are merely projections and, as such, are based exclusively on the expectations of the Executive Board as to the future of businesses. This performance report includes non-accounting and accounting data, such as operational and financial data, in addition to projections based on the Company management's expectation. The non-accounting data, including EBITDA, were not subject to the review of the Company's independent auditors.

**Management representation**

In accordance with the provisions of CVM Rule No. 480, we represent that we have discussed, reviewed and agreed with the financial statements and the independent auditor's report on the quarterly information for the period ended September 30, 2013.

**Acknowledgements**

We would like to thank our employees for their concerted efforts, commitment and talent which enabled us to achieve such promising results, and also our customers and shareholders for the trust placed on us.

## Notes to the quarterly information

## 1. Operations

Diagnósticos da América S/A (Company) is a publicly-held corporation located in the city of Barueri, São Paulo State, with its registration granted by the Brazilian Securities Commission (CVM) for the trading of its securities on the stock market on November 5, 2004 , and has been listed on the Novo Mercado segment of Bovespa since November 19, 2004, under code DASA3.

The Company's business purpose is to render services directly to individuals or through health insurance plans, insurance companies, medical-hospital assistance entities, other entities for healthcare financing, in the following areas: (i) clinical analysis, directly or through contracted laboratories; and (ii) other auxiliary diagnostic support services (SAD), exclusively through specialized clinics, as, for instance, in the following areas: a) cytology and pathologic anatomy; b) diagnostic by imaging and graphic methods; and c) nuclear medicine. As Management does not control them separately in their business process, they are not being recognized as reportable segments.

In addition, it explores activities related to: (i) tests in food and substances to evaluate risks for the human being; (ii) import, for its own use, of medical-hospital equipment, sets for diagnostics and related material in general; (iii) preparation, edition, publishing and distribution of newspapers, books, magazines, periodicals and other written media on scientific researches and activities developed by the Company; (iv) granting and administration of business franchising including advertising and publishing fund, training and selection of labor, supplying of equipment and research material suppliers, among others. The Company operates in lab-to-lab business (support to laboratories) through the Álvaro brand, and began offering services in the public health sector through the CientíficaLab brand. The Company can also hold equity interest in other entities.

The Company ended the quarter with 521 operating units:

| Brands | State | 9/30/2013 | 12/31/2012 |
|---|---|---|---|
| Delboni Auriemo (i) | São Paulo | **42** | 41 |
| Lavoisier | São Paulo | **76** | 81 |
| Bronstein | Rio de Janeiro | **41** | 42 |
| Lâmina (i) | Rio de Janeiro | **14** | 13 |
| Pasteur | Brasília | **25** | 23 |
| Frischmann | Paraná | **39** | 42 |
| Image | Bahia | **4** | 4 |
| Laboratório Álvaro | Paraná | **14** | 14 |
| LabPasteur | Ceará | **18** | 18 |
| Vita-Lâmina | Santa Catarina | **2** | 2 |
| Atalaia | Goiás | **22** | 21 |
| Exame | Brasília | **24** | 22 |
| MedImagem | Rio de Janeiro | **7** | 7 |
| Hospital Mãe de Deus | Rio Grande do Sul | **3** | 2 |
| Cedic/Cedilab | Mato Grosso | **10** | 11 |
| Unimagem | Ceará | **1** | 1 |
| CERPE | Pernambuco | **37** | 40 |
| Sérgio Franco | Rio de Janeiro | **80** | 78 |
| Proecho | Rio de Janeiro | **15** | 15 |
| Multi Imagem | Rio de Janeiro | **6** | 6 |
| CDPI | Rio de Janeiro e São Paulo | **7** | 7 |
| Previlab | São Paulo | **18** | 19 |
| Cytolab | São Paulo | **13** | 12 |
| Alta Excelência Diagnóstica – *Premium* | São Paulo | **3** | 2 |
| | | **521** | 523 |

(i) At September 30, 2013, the brand Club DA had 23 units, 19 of them linked to the brand Delboni Auriemo and 4 units linked to the brand Lâmina.

In addition, CientificaLab operates in the public healthcare segment, and the revenue arises from agreements entered into with customers in this segment. This operation ended the third quarter of 2013 with 29 clients, with exam requisitions totaling 1.5 million and 4,588 million for the three and nine-month period ended September 30, 2013, respectively. CientificaLab has 591 collection units, 81 of them are hospitals and 510 are Outpatient clinics not related to the units listed above.

The information above is not comprised by the auditor's review scope.

## 2. Agreement on Preservation of Reversibility of Operation (“APRO”)

On October 26, 2011, the Company and the Administrative Council for Economic Defense ("CADE") executed an Agreement on Preservation of Reversibility of Operation, in the case records of Concentration Act nº 08012.010038/2010-43, an Agreement to Preserve Reversibility of Transactions (“APRO”), referring to the subject matter of the Contract of Association executed on December 7, 2010, for acquisition of MD1 Group companies (“Transaction”), upon direct acquisition and purchase of shares, as approved in the Special General Meeting held on January 5, 2011. The purpose of APRO is to prevent, until the judgment of merit of the Concentration Act and relating to the companies that are the subject matter of the Operation (MD1 Group), irreversible amendments or amendments of difficult reparation, thus ensuring the reversibility of the Operation in the event that, upon judgment of the merits, CADE understands that the imposition of restrictions will be necessary. The execution of the APRO does not imply that CADE will be bound by the analysis of the merit or any anticipation related to the result of this judgment, nor does it bind the Company to reverse the integration measures adopted prior to its execution.

As provided for in the APRO, the Company engaged an independent auditor, BDO RCS Auditores Independentes, to attest to the fulfillment of the Agreement. In all bi-monthly reports already issued by BDO, the auditors concluded that all the requirements set forth in the APRO regarding the obligations to be fulfilled by the parties have been complied with.

Based on the opinion of its legal counsels, the Company concluded that, for purposes of compliance with the information disclosure obligations provided, DASA is not a related party of the companies of Amil Group, given that such companies are not controlled by and do not control DASA, are not under common direct or indirect control and their controllers have no material influence on DASA.

The Economic Supervision Office of the Ministry of Finance (SEAE) issued, on March 5, 2012, technical opinion No. 06145/2012/RJ regarding the Concentration Act entered into between Diagnósticos da América S/A and MD1 Diagnósticos S/A. The document, which contains merely an opinion, recommends the approval of the operation taking into account the restrictions detailed therein. The issuance of said opinion does not imply any binding of CADE to the analysis of the merit or anticipation of the results of the judgment of the operation by this body. The opinion issued by the SEAE is, apparently, based on assumptions of partial data regarding the interpretations given to the corporate relationship maintained between DASA, the individuals linked to JHSPE Empreendimentos and its subsidiaries, Amil Participações S.A and its subsidiaries, and FMG Empreendimentos Hospitalares. The technical opinion is available on the Internet, at

http://www.fazenda.gov.br/littera/pdf/08012010038201043.pdf.

SEAE's opinion will not reverse the integration measures adopted as of the date of execution of the APRO, such as the merger of MD1 Participações Ltda. into the Company. The operation is still being analyzed by the CADE, and the Company maintains an active cooperation towards the positive results of the judgment. In this context, we are certain that the CADE will be able to make an appropriate and careful analysis of the market data and the corporate relationships existing between some shareholders and third parties, so as to conclude that the operation does not involve competition concerns, contrary to what is suggested by SEAE's opinion.

Particularly, we understand that the CADE will analyze two relevant events that took place after the issuance of SEAE's opinion: the termination of the indirect corporate relationship between FMG Empreendimentos Hospitalares and Amil Participações S.A., as per the material fact announced by the latter on September 25, 2012; and ii) the disposal of share control of Amil Participações S.A. by some individual shareholders linked to JHSPE Empreendimentos to the UnitedHealth Group Incorporated (UHG), as disclosed to the market through the material fact issued on October 8, 2012 by Amil Participações S.A. The Company understands that these facts relevantly affect the interpretations included in SEAE's opinion on the operation and provide a positive contribution to the analysis of competition matters.

The Company is also certain that CADE will analyze the pro-competition effects of the operation, which would bring significant efficiency to the sector of auxiliary diagnostic support services. The Company will continue to offer active cooperation to CADE, looking forward to its approval in a timely manner.

## 3. Consolidation procedures

The Quarterly information comprises the statements of the Company and the following subsidiaries:

| | % Equity in consolidation | |
|---|---|---|
| | **09/30/2013** | **12/31/2012** |
| **Direct subsidiaries:** | | |
| DASA Real Estate Empreendimentos Imobiliários Ltda. | **99.99%** | 99.99% |
| CientificaLab Produtos Laboratoriais e Sistemas Ltda. | **75.95%** | 99.99% |
| DASA Finance Corporation | **100.00%** | 100.00% |
| Instituto de Endocrinologia e Medicina Nuclear do Recife S.A. (CERPE) | **100.00%** | 100.00% |
| DASA Log Empreendimentos Ltda. | **99.00%** | 99.00% |
| DASA Sudoeste Participações Ltda. | **99.00%** | 99.00% |
| DASA Nordeste Participações Ltda. | **99.00%** | 99.00% |
| DASA Centro-Oeste Participações Ltda. | **99.00%** | 99.00% |
| DASA Property Participações Ltda. | **99.00%** | 99.00% |
| Pro Echo Cardiodata Serviços Médicos Ltda. | **69.58%** | 69.58% |
| CRMI - Clínica de Ressonância e Multi Imagem Ltda. | **99.99%** | 99.99% |
| CDPI - Clínica de Diagnóstico por Imagem Ltda. | **99.99%** | 99.99% |
| Laboratórios Médicos Dr.Sérgio Franco Ltda. | **99.99%** | 99.99% |
| Previlab Análises Clínicas Ltda. | **99.56%** | 99.56% |
| **Indirect subsidiaries:** | | |
| Pro Echo Cardiodata Serviços Médicos Ltda. | **30.42%** | 30.42% |
| Clínica de Ressonância e Multi-Imagem Caxias Ltda. | **99.99%** | 99.99% |
| Clínica de Ressonância e Multi-Imagem Petrópolis Ltda. | **70.00%** | 70.00% |
| Imagem e Diagnóstico Ltda. | **99.99%** | 99.99% |
| Check-Up UP - Unidade Prevent., Diagn. e Medicina Preventiva Ltda. | **99.99%** | 99.99% |
| INCEBRAS Instituto Brasileiro da Coluna e do Cerébro Ltda. | **29.00%** | 29.00% |
| Multimagem PET S/A. | **100.00%** | 100.00% |
| STAT Análises Clínicas Ltda. | **99.66%** | 99.66% |
| CientificaLab Produtos Laboratoriais e Sistemas Ltda. | **24.05%** | - |

## Notes to the quarterly information

## 4. Basis for preparation of quarterly financial statements

### 4.1. Statement of compliance (with respect to IFRS and CPC standards)

The quarterly financial information includes:

- The consolidated quarterly financial information prepared in accordance with technical pronouncement CPC 21(R1) – Interim Financial Reporting and IAS 34 – Interim Financial Reporting issued by the International Accounting Standards Board (IASB) and presented pursuant to the rules issued by the Brazilian Securities and Exchange Commission (CVM).

- The Company's individual quarterly financial information prepared in accordance technical pronouncement CPC 21(R1) – Interim Financial Reporting.

The issuance of individual and consolidated quarterly financial information was authorized by Board of Directors meeting held on November 11, 2013.

### 4.2. Basis for measurement

The individual and consolidated Quarterly financial information were prepared on the basis of historical cost, with except for the following items recognized in the statement of financial position: (i) derivative financial instruments measured at fair value; and (ii) non-derivative financial instruments measured at fair value thought profit or loss.

### 4.3. Functional and reporting currency

The individual and consolidated Quarterly financial information are presented in Reais (R$), which is the Company's functional currency, all financial information presented in Reais was rounded off to the nearest thousand, except when otherwise indicated.

### 4.4. Use of estimates and judgment

The preparation of the individual and consolidated Quarterly financial information in accordance with IFRS and CPC standards requires Management to make judgments, estimates and assumptions that may affect the application of accounting policies and the reported values of assets, liabilities, revenue and expenses. Actual results may differ from such estimates.

Estimates and assumptions are permanently reviewed. Reviews relating to accounting estimates are recorded in the period in which the estimates are reviewed, as well as in any other future periods affected.

Uncertainties about the assumptions or estimates that may pose significant risks of material adjustments in the following reporting period are detailed in the following notes:

- Note 9 - Trade accounts receivable

- Note 21 - Provision for tax, social security, labor and civil risks

- Note 26 – Assumptions used for determining the fair value of financial instruments.

### 4.5. Segregation between current and noncurrent

Except for deferred taxes, the Company segregated all equity items that are expected to be realized within twelve months as from the date of the Quarterly financial information as current.

## Notes to the quarterly information

### 4.6. Statement of comprehensive income

There were no equity transactions resulting in adjustments that might be recorded in the statement of comprehensive income, that is, income for the period equals comprehensive income.

## 5. Significant accounting practices

The Company represents that the quarterly information (ITR) is presented in accordance with the accounting practices presented in Note 5 of the financial statements for the year ended December 31, 2012.

The pronouncements CPC 19 (R2), CPC 36 (R3), CPC 45, CPC 46, applicable as from 2013, did not cause any impact on the Company's quarterly information.

## 6. Determination of fair values

A number of the Company's accounting policies and disclosures require the determination of fair value, for financial and non-financial assets and liabilities. The fair value has been calculated for measurement and/or disclosure purposes, consistently with the methods described in Note 6 of the financial statements for the year ended December 31, 2012, and must be analyzed together with these financial statements. Additional information on assumptions used for determination of fair value is disclosed in specific notes of the respective assets or liabilities, where applicable.

## 7. Cash and cash equivalents

| | Company | | Consolidated | |
|---|---|---|---|---|
| | **9/30/2013** | **12/31/2012** | **9/30/2013** | **12/31/2012** |
| Cash and banks | **7,982** | 12,669 | **32,281** | 16,087 |
| Marketable securities | **154,519** | 139,877 | **190,479** | 212,432 |
| | **162,501** | 152,546 | **222,760** | 228,519 |

Cash and cash equivalents classified in consolidated current assets are presented below:

| | 9/30/2013 | | 12/31/2012 | |
|---|---|---|---|---|
| | **Amount** | **Average yield for the period** | **Amount** | **Average yield for the period** |
| Cash and banks | **32,281** | - | 16,087 | - |
| Bank Deposit Certificate (CDB) / Repurchase agreements | **50,601** | **103.73% of Interbank Deposit Certificate (CDI)** | - | - |
| Fixed income fund | **139,878** | **102,66% of CDI** | 212,432 | 103.66% of CDI |
| | **222,760** | | 228,519 | |

Bank deposits represent balances in banks and immediate liquidity rights of which the use is not subject to any restrictions.

Marketable securities are readily redeemable from the issuer into a known cash amount and are subject to insignificant risk of change in value.

## Notes to the quarterly information

# 8. Marketable securities

| | | Company | | | |
|---|---|---|---|---|---|
| | | 9/30/2013 | | 12/31/2012 | |
| | Currency | Amount (R$) | Average yield for the period | Amount (R$) | Average yield for the period |
| CDB / Repurchase agreements (a) | R$ | **7,398** | **101,01% of CDI** | - | - |
| Fixed income fund (a) | R$ | **20,274** | **102.59% of CDI** | 46,803 | 102.63% of CDI |
| | | **27,672** | | 46,803 | |
| Current assets | | **-** | | - | |
| Noncurrent assets | | **27,672** | | 46,803 | |

| | | Consolidated | | | | | |
|---|---|---|---|---|---|---|---|
| | | 9/30/2013 | | | 12/31/2012 | | |
| | Currency | Amount (US$) | Amount (R$) | Average yield for the period | Amount (US$) | Amount (R$) | Average yield for the period |
| CDB / Repurchase agreements (a) | R$ | **-** | **9,277** | **101,01% of CDI** | - | - | - |
| Fixed income fund (a) | R$ | **-** | **29,802** | **102.59% of CDI** | - | 57,635 | 101.70% of CDI |
| Brazilian government bonds | US$ | **3,391** | **7,560** | **2.92% p.a.** | 9,515 | 19,443 | 1.76% p.a. |
| Corporate bonds | US$ | **9,917** | **22,115** | **5.25% p.a.** | 6,122 | 12,510 | 4.74% p.a. |
| | | | **68,754** | | | 89,588 | |
| Current assets | | | **(29,675)** | | | (31,953) | |
| Noncurrent assets | | | **39,079** | | | 57,635 | |

(a) The consolidated amount of R$39.079 (57.635 at December 31, 2012) invested in fixed income funds and CDB / Committed transactions corresponds to guarantee for payment of contingencies that may be demanded from acquired companies, for a period of up to 6 years from the date of acquisition.

# 9. Trade accounts receivable

| | Company | | Consolidated | |
|---|---|---|---|---|
| | 9/30/2013 | 12/31/2012 | 9/30/2013 | 12/31/2012 |
| **Current** | | | | |
| Trade notes receivable: | | | | |
| Falling due | **251,668** | 216,209 | **355,378** | 288,535 |
| Amounts overdue **(b)** | **137,119** | 178,985 | **189,180** | 230,834 |
| | **388,787** | 395,194 | **544,558** | 519,369 |
| Other accounts receivable: | | | | |
| Checks receivable | **726** | 381 | **1,184** | 435 |
| Bounced check | **763** | 1,080 | **1,442** | 1,699 |
| Credit card | **16,497** | 1,458 | **17,741** | 3,434 |
| Unbilled health plans **(a)** | **61,649** | 48,690 | **104,916** | 82,738 |
| | **79,635** | 51,609 | **125,283** | 88,306 |
| Total receivable: | **468,422** | 446,803 | **669,841** | 607,675 |
| Deducted of: | | | | |
| Allowance for doubtful accounts due to disallowance, default and returned checks | **(58,221)** | (91,991) | **(77,285)** | (109,220) |
| | **410,201** | 354,812 | **592,556** | 498,455 |

## Notes to the quarterly information

(a) Refers to amounts of services rendered and not yet billed until to the closing of the quarter. Services not billed within 120 days are written off from account Agreements to be billed.

(b) The aging of overdue balances is presented below:

| | | Company | | | | | |
|---|---|---|---|---|---|---|---|
| | | 9/30/2013 | | | 12/31/2012 | | |
| | % | Gross amount | Provision for loss | Net amount | Gross amount | Provision for loss | Net amount |
| 0 to 30 | | **35,171** | **-** | **35,171** | 37,344 | - | 37,344 |
| 31 to 60 | | **13,464** | **-** | **13,464** | 18,731 | - | 18,731 |
| 61 to 90 | | **10,728** | **-** | **10,728** | 11,959 | - | 11,959 |
| 91 to 120 | 25% | **9,541** | **(2,384)** | **7,157** | 10,849 | (2,712) | 8,137 |
| 121 to 180 | 50% | **15,072** | **(7,536)** | **7,536** | 12,713 | (6,357) | 6,356 |
| 181 to 360 | 75% | **22,421** | **(16,816)** | **5,605** | 22,187 | (16,640) | 5,547 |
| Over 360 | 100% | **30,722** | **(30,722)** | **-** | 65,202 | (65,202) | - |
| | | **137,119** | **(57,458)** | **79,661** | 178,985 | (90,911) | 88,074 |
| Returned checks | | **763** | **(763)** | **-** | 1,080 | (1,080) | - |
| | | **137,882** | **(58,221)** | **79,661** | 180,065 | (91,991) | 88,074 |

| | | Consolidated | | | | | |
|---|---|---|---|---|---|---|---|
| | | 9/30/2013 | | | 12/31/2012 | | |
| | % | Gross amount | Provision for loss | Net amount | Gross amount | Provision for loss | Net amount |
| 0 to 30 | | **48,473** | **-** | **48,473** | 51,618 | - | 51,618 |
| 31 to 60 | | **20,972** | **-** | **20,972** | 24,803 | - | 24,803 |
| 61 to 90 | | **14,541** | **-** | **14,541** | 18,939 | - | 18,939 |
| 91 to 120 | 25% | **13,689** | **(3,421)** | **10,268** | 16,105 | (4,026) | 12,079 |
| 121 to 180 | 50% | **20,836** | **(10,418)** | **10,418** | 17,453 | (8,727) | 8,726 |
| 181 to 360 | 75% | **34,654** | **(25,989)** | **8,665** | 28,592 | (21,444) | 7,148 |
| Over 360 | 100% | **36,015** | **(36,015)** | **-** | 73,324 | (73,324) | - |
| | | **189,180** | **(75,843)** | **113,337** | 230,834 | (107,521) | 123,313 |
| Returned checks | | **1,442** | **(1,442)** | **-** | 1,699 | (1,699) | - |
| | | **190,622** | **(77,285)** | **113,337** | 232,533 | (109,220) | 123,313 |

The collection process for diagnostic support services provided by the Company is complex due to a variety of factors, including the large number of health plans used and different coverage offered. This complexity has historically given rise to loss due to disallowances. To a lesser extent, there are also losses due to default.

Disallowances mainly refer to: (i) operating issues, such as services rendered to customers of health care plans without previous authorization; (ii) sales issues, such as new price lists agreed, which have not been updated on both systems; and (iii) technical issues, such as different interpretations of examination requisitions.

## Notes to the quarterly information

To cover the losses as a result of such disallowances and default, Management adopts the policy of recording a provision for losses from disallowances and default based on receivables overdue for more than 90 days, as shown below:

| Overdue receivables: | % of provision |
|---|---|
| 91 and 120 days | 25% |
| 121 and 180 days | 50% |
| 181 and 360 days | 75% |
| Above 360 days | 100% |

In the nine-month period ended September 30, 2013, losses due to disallowance and default total 4% of the gross operating income (3% in the nine-month period ended September 30, 2012). This increase was caused specifically by the non-recurrent additional allowance set up for receivables from two health care company.

From 2012, the Company began to adopt the accounting practice of derecognize any receivables overdue over 2 years against the allowance. In the nine-month period ended September 30, 2013, R$ 57,969 (R$ 19,563 at December 31, 2012) were derecognized following this criteria, including R$ 15,803 referring to a judicial collection claim with low likelihood of success.

The Company also adopts the criterion to set up an allowance for 100% of the checks returned due to insufficient funds. At September 30, 2013, such allowance amounted to R$ 763 (R$ 1,080 at December 31, 2012) Company, and R$ 1,442 (R$ 1,699 at December 31, 2012) consolidated.

Given that receivables from credit cards companies are historically fully paid, the Company has not set up an allowance for losses in this account.

In nine-month period ended September 30, 2013, changes in allowances for doubtful accounts due to disallowance, default and returned checks due to insufficient funds, in consolidated, is as follows:

| | | |
|---|---|---|
| Balance at December 31, 2012 | | (109,220) |
| Additions | | |
| Allowance for doubtful accounts due to disallowance and default | (76,401) | |
| Allowance for returned checks | 257 | |
| | (76.144) | |
| Reversal and derecognition | | |
| Reversal of allowance for disallowance and default due to payment and proper disallowance | 50,110 | |
| Derecognition of provision for receivables overdue for more than 2 years | 57,969 | |
| | 108.079 | |
| Net changes of provisions | | 31.935 |
| Balance at September 30, 2013 | (77,285) | |

## Notes to the quarterly information

## 10. Inventories

| | Company | | Consolidated | |
|---|---|---|---|---|
| | 9/30/2013 | 12/31/2012 | 9/30/2013 | 12/31/2012 |
| Direct material - domestic | **22,224** | 18,265 | **32,200** | 32,523 |
| Direct material – imported | **6,127** | 7,301 | **9,724** | 11,399 |
| Secondary material - domestic | **7,595** | 9,661 | **10,936** | 12,211 |
| Supplies | **3,979** | 4,483 | **5,864** | 5,854 |
| Provision for obsolescence | **(737)** | (250) | **(1,188)** | (545) |
| | **39,188** | 39,460 | **57,536** | 61,442 |

## 11. Taxes recoverable

| | Company | | Consolidated | |
|---|---|---|---|---|
| | 09/30/13 | 12/31/12 | 09/30/13 | 12/31/12 |
| Income tax (IR) – withholding at marketable securities | **1,551** | - | **1,848** | 194 |
| Income and social contribution taxes (IR/CS) - withholding at source on billing | **36,286** | 6,736 | **43,770** | 10,376 |
| IR/CS – prepayment for the period | **-** | - | **25,585** | 3,824 |
| IR/CS – credits recoverable from prior years | **19,360** | 42,055 | **31,730** | 56,362 |
| Contribution Tax on Gross Revenue for Social Integration Program (PIS) and Contribution Tax on Gross Revenue for Social Security Financing (COFINS) – withholding at source on billing | **19,962** | 18,916 | **26,509** | 25,306 |
| Service Tax (ISS) - withholding at source on billing | **5,143** | 5,213 | **13,310** | 12,440 |
| National Institute for Social Security (INSS) recoverable | **4,706** | 3,442 | **25,790** | 23,794 |
| Other | **6,082** | 5,680 | **6,643** | 6,166 |
| | **93,090** | 82,042 | **175,185** | 138,462 |

## 12. Investments

### a) Information on investments in subsidiaries

| | Company | | Consolidated | |
|---|---|---|---|---|
| | 9/30/2013 | 12/31/2012 | 9/30/2013 | 12/31/2012 |
| DASA Real Estate Empreendimentos Imobiliários Ltda. | **29,613** | 30,969 | **-** | - |
| CientificaLab Produtos Laboratoriais e Sistemas Ltda. | **86,993** | 83,019 | **-** | - |
| Instituto de Endocrinologia e Medicina Nuclear do Recife S.A. (CERPE) | **33,322** | 29,370 | **-** | - |
| CDPI - Clínica de Diagnóstico por Imagem Ltda. | **40,658** | 38,459 | **-** | - |
| CRMI - Clínica de Ressonância e Multi Imagem Ltda. | **13,299** | 10,768 | **-** | - |
| Pro Echo Cardiodata Serviços Médicos Ltda. | **88,066** | 83,914 | **-** | - |
| Laboratórios Médicos Dr. Sérgio Franco Ltda. | **112,589** | 101,820 | **-** | - |
| Previlab - Analises Clinicas Ltda. | **24,869** | 23,035 | **-** | - |
| Dasa Property Participações Ltda. | **51** | 50 | **-** | - |
| Dasa Nordeste Participações Ltda | **51** | 50 | **-** | - |
| Dasa Centro Oeste Participações Ltda. | **51** | 50 | **-** | - |
| Dasa Sudoeste Participações Ltda. | **51** | 50 | **-** | - |
| | **429,613** | 401,554 | **-** | - |
| Other investments | **626** | 361 | **779** | 516 |
| | **430,239** | 401,915 | **779** | 516 |

## Notes to the quarterly information

| Subsidiary | Reporting date | Number of units of interest/ shares | Number of unites of interest/ shares held | Interest in paid-in capital (%) | Paid-in capital | Equity (capital deficiency) | Income (loss) for the period |
|---|---|---|---|---|---|---|---|
| DASA Real Estate | 9/30/2013 | 25,667,079 | 25,667,078 | 99.99 | 25,667 | 29,613 | (956) |
| | 12/31/2012 | 25,667,079 | 25,667,078 | 99.99 | 25,667 | 30,969 | 9,170 |
| CientíficaLab | 9/30/2013 | 70,676,629 | 53,676,628 | 75.95 | 70,677 | 102,591 | (11,526) |
| | 12/31/2012 | 27,176,629 | 27,176,628 | 99.99 | 38,177 | 83,019 | (13,588) |
| DASA Finance (i) | 9/30/2013 | 50,000 | 50,000 | 100 | 22,565 | (16,031) | (12,386) |
| | 12/31/2012 | 50,000 | 50,000 | 100 | 80 | (26,130) | (4,219) |
| CERPE | 9/30/2013 | 122,024 | 120,804 | 99.00 | 122 | 33,322 | 4,230 |
| | 12/31/2012 | 122,024 | 120,804 | 99.00 | 122 | 29,370 | (2,467) |
| CDPI | 9/30/2013 | 1,834,280 | 1,834,279 | 99.99 | 18,343 | 40,658 | 2,199 |
| | 12/31/2012 | 1,834,280 | 1,834,279 | 99.99 | 18,343 | 38,459 | 7,391 |
| CRMI | 9/30/2013 | 2,508,000 | 2,507,999 | 99.99 | 2,508 | 13,299 | 2,890 |
| | 12/31/2012 | 2,508,000 | 2,507,999 | 99.99 | 2,508 | 10,768 | 2,556 |
| Pro Echo | 9/30/2013 | 131,483,058 | 91,483,058 | 69.58 | 131,483 | 126,568 | 4,152 |
| | 12/31/2012 | 131,483,058 | 91,483,058 | 69.58 | 131,483 | 120,428 | 179 |
| Lab. Méd. Dr. Sérgio Franco | 9/30/2013 | 63,902,082 | 63,902,081 | 99.99 | 63,902 | 112,589 | 52,889 |
| | 12/31/2012 | 63,902,082 | 63,902,081 | 99.99 | 63,902 | 101,820 | 71,257 |
| Previlab | 9/30/2013 | 23,113,314 | 23,009,743 | 99.56 | 23,113 | 24,869 | 1,834 |
| | 12/31/2012 | 23,113,314 | 23,009,743 | 99.56 | 21,198 | 23,035 | - |
| Dasa Property Part. | 9/30/2013 | 50,000 | 49,500 | 99.00 | 50 | 51 | 1 |
| | 12/31/2012 | 50,000 | 49,500 | 99.00 | 50 | 50 | - |
| Dasa Nordeste Part. | 9/30/2013 | 50,000 | 49,500 | 99.00 | 50 | 51 | 1 |
| | 12/31/2012 | 50,000 | 49,500 | 99.00 | 50 | 50 | - |
| Dasa Centro Oeste Part. | 9/30/2013 | 50,000 | 49,500 | 99.00 | 50 | 51 | 1 |
| | 12/31/2012 | 50,000 | 49,500 | 99.00 | 50 | 50 | - |
| Dasa Sudoeste Part. | 9/30/2013 | 50,000 | 49,500 | 99.00 | 50 | 51 | 1 |
| | 12/31/2012 | 50,000 | 49,500 | 99.00 | 50 | 50 | - |

(i) Investment in DASA Finance is classified in current liabilities of the Company for presenting negative equity.

### b) Changes in investments

| | Balance at December 31, 2012 | Capital increase | Dividends | Equity pickup | Balance at September 30, 2013 |
|---|---|---|---|---|---|
| DASA Real Estate | 30,969 | **-** | **(400)** | **(956)** | **29,613** |
| CientíficaLab | 83,019 | **15,500** | **-** | **(11,526)** | **86,993** |
| CERPE | 29,370 | **-** | **(278)** | **4,230** | **33,322** |
| CDPI | 38,459 | **-** | **-** | **2,199** | **40,658** |
| CRMI | 10,768 | **-** | **(359)** | **2,890** | **13,299** |
| Pro Echo | 83,914 | **-** | **-** | **4,152** | **88,066** |
| Lab. Méd. Dr. Sérgio Franco | 101,820 | **-** | **(42,120)** | **52,899** | **112,589** |
| Previlab | 23,035 | **-** | **-** | **1,834** | **24,869** |
| Dasa Property Part. | 50 | **-** | **-** | **1** | **51** |
| Dasa Nordeste Part. | 50 | **-** | **-** | **1** | **51** |
| Dasa Centro Oeste Part. | 50 | **-** | **-** | **1** | **51** |
| Dasa Sudoeste Part. | 50 | **-** | **-** | **1** | **51** |
| | 401,554 | **15,500** | **(43,157)** | **55,716** | **429,613** |
| Negative equity | | | | **(12,386)** | **(16,031)** |
| | | | | **43,330** | **413,582** |

## Notes to the quarterly information

(ii) As private instruments of change and consolidation of Articles of Incorporation registered with the São Paulo State Commercial Registry (JUCESP) on January 7 and June 4, 2013, the Company increased the capital of the subsidiary Cientificalab by R$11,500 and R$4,000, respectively. The partner DASA Real Estate increased the capital of Cientificalab by R$17,000, pursuant to the instrument registered on June 4, 2013. After the corresponding payments, the interest held by the Company and the subsidiary DASA in the capital of the subsidiary Cientificalab totaled R$53,677 (75.95%) and R$17,000 (24.05%), respectively.

## 13. Property and equipment, net

| | | Company | | | |
|---|---|---|---|---|---|
| | | 9/30/2013 | | | 12/31/2012 |
| | Average depreciation rate% p.a. | Cost | Accumulated depreciation | Net | Net |
| Properties | 4.00 | **824** | **(545)** | **279** | 312 |
| Leasehold improvements | 7.80 | **389,601** | **(244,896)** | **144,705** | 145,515 |
| Machinery and equipment | 7.05 | **344,465** | **(106,357)** | **238,108** | 252,109 |
| Furniture and fixtures | 10.12 | **41,635** | **(15,902)** | **25,733** | 27,518 |
| Facilities | 8.37 | **36,193** | **(11,306)** | **24,887** | 20,726 |
| IT equipment | 10.69 | **116,665** | **(56,907)** | **59,758** | 60,354 |
| Vehicles | 19.17 | **3,687** | **(3,342)** | **345** | 594 |
| Library | 7.48 | **147** | **(124)** | **23** | 32 |
| Land | - | **180** | **-** | **180** | 180 |
| Acquisitions in progress | - | **31,350** | **-** | **31,350** | 32,468 |
| | | **964,747** | **(439,379)** | **525,368** | 539,808 |

| | | Consolidated | | | |
|---|---|---|---|---|---|
| | | 9/30/2013 | | | 12/31/2012 |
| | Average depreciation rate % p.a. | Cost | Accumulated depreciation | Net | Net |
| Properties | 4.00 | **4,564** | **(1,580)** | **2,984** | 3,128 |
| Leasehold improvements | 8.14 | **472,656** | **(279,615)** | **193,041** | 198,178 |
| Machinery and equipment | 6.17 | **460,234** | **(152,866)** | **307,368** | 319,432 |
| Furniture and fixtures | 9.21 | **57,561** | **(19,964)** | **37,597** | 40,224 |
| Facilities | 11.52 | **58,428** | **(22,222)** | **36,206** | 31,877 |
| IT equipment | 11.24 | **119,915** | **(56,470)** | **63,445** | 65,132 |
| Vehicles | 19.55 | **5,366** | **(4,935)** | **431** | 839 |
| Library | 5.15 | **233** | **(213)** | **20** | 41 |
| Land | - | **6,574** | **-** | **6,574** | 6,574 |
| Acquisitions in progress | - | **45,251** | **-** | **45,251** | 51,049 |
| | | **1,230,782** | **(537,865)** | **692,917** | 716,474 |

Changes in cost

| | Company | | | | |
|---|---|---|---|---|---|
| | | Changes in the period | | | |
| | 12/31/2012 Restated (a) | Additions | Write-offs | Transfers | 9/30/2013 |
| Properties | 824 | **-** | **-** | **-** | **824** |
| Leasehold improvements | 370,096 | **15,896** | **(1,252)** | **4,861** | **389,601** |
| Machinery and equipment | 335,624 | **22,126** | **(13,920)** | **635** | **344,465** |
| Furniture and fixtures | 39,211 | **2,727** | **(303)** | **-** | **41,635** |
| Facilities | 29,617 | **5,784** | **-** | **792** | **36,193** |
| IT equipment | 103,448 | **12,903** | **(1,056)** | **1,370** | **116,665** |
| Vehicles | 3,822 | **39** | **(174)** | **-** | **3,687** |
| Library | 147 | **-** | **-** | **-** | **147** |
| Land | 180 | **-** | **-** | **-** | **180** |
| Acquisitions in progress | 32,468 | **8,971** | **(613)** | **(9,476)** | **31,350** |
| | 915,437 | **68,446** | **(17,318)** | **(1,818)** | **964,747** |

## Notes to the quarterly information

| | Consolidated | | | | |
|---|---|---|---|---|---|
| | | Changes in the period | | | |
| | 12/31/2012 Restated (a) | Additions | Write-offs | Transfers | 9/30/2013 |
| Properties | 4,564 | **-** | **-** | **-** | **4,564** |
| Leasehold improvements | 451,728 | **16,940** | **(1,252)** | **5,240** | **472,656** |
| Machinery and equipment | 440,573 | **26,223** | **(14,198** | **7,636** | **460,234** |
| Furniture and fixtures | 54,459 | **3,090** | **(326)** | **338** | **57,561** |
| Facilities | 50,143 | **7,465** | **(1)** | **821** | **58,428** |
| IT equipment | 105,857 | **13,265** | **(1,117)** | **1,910** | **119,915** |
| Vehicles | 5,954 | **39** | **(755)** | **128** | **5,366** |
| Library | 233 | **-** | **-** | **-** | **233** |
| Land | 6,574 | **-** | **-** | **-** | **6,574** |
| Acquisitions in progress | 51,049 | **11,014** | **(615)** | **(16,197)** | **45,251** |
| | 1,171,134 | **78,036** | **(18,264)** | **(124)** | **1,230,782** |

(a) For better presentation, the accumulated depreciation of certain assets items was offset with their respective cost in order to reflect their deemed cost adopted upon implementation of IFRS and CPC standards.

<u>Changes in accumulated depreciation</u>

| | Company | | | |
|---|---|---|---|---|
| | | Changes in the period | | |
| | 12/31/2012 Restated (a) | Additions | Write-offs | 9/30/2013 |
| Properties | (512) | **(33)** | **-** | **(545)** |
| Leasehold improvements | (224,581) | **(20,317)** | **2** | **(244,896)** |
| Machinery and equipment | (83,515) | **(29,814)** | **6,972** | **(106,357)** |
| Furniture and fixtures | (11,693) | **(4,369)** | **160** | **(15,902)** |
| Facilities | (8,891) | **(2,415)** | **-** | **(11,306)** |
| IT equipment | (43,094) | **(14,672)** | **859** | **(56,907)** |
| Vehicles | (3,228) | **(283)** | **169** | **(3,342)** |
| Library | (115) | **(9)** | **-** | **(124)** |
| | (375,629) | **(71,912)** | **8,162** | **(439,379)** |

| | Consolidated | | | | |
|---|---|---|---|---|---|
| | | Changes in the period | | | |
| | 12/31/2012 Restated (a) | Additions | Write-offs | Transfers | 9/30/2013 |
| Properties | (1,436) | **(144)** | **-** | **-** | **(1,580)** |
| Leasehold improvements | (253,550) | **(26,067)** | **2** | **-** | **(279,615)** |
| Machinery and equipment | (121,141) | **(38,410)** | **7,104** | **(419)** | **(152,866)** |
| Furniture and fixtures | (14,235) | **(5,564)** | **173** | **(338)** | **(19,964)** |
| Facilities | (18,266) | **(3,936)** | **-** | **(20)** | **(22,222)** |
| IT equipment | (40,725) | **(16,154)** | **907** | **(498)** | **(56,470)** |
| Vehicles | (5,115) | **(411)** | **719** | **(128)** | **(4,935)** |
| Library | (192) | **(21)** | **-** | **-** | **(213)** |
| | (454,660) | **(90,707)** | **8,905** | **(1,403)** | **(537,865)** |

(a) For better presentation, the accumulated depreciation of certain assets items was offset with their respective cost in order to reflect their deemed cost upon implementation of IFRS and CPC standards.

Additions to accumulated depreciation, stated in changes for the period, were partly recorded under general and administrative expenses and partly under costs of goods and/or services sold.

During the quarter, the Company did not identify any assets impairment indicator.

## Notes to the quarterly information

## 14. Intangible assets

| | Company | | | | | | |
|---|---|---|---|---|---|---|---|
| | Average amortization rate % p.a. | 9/30/2013 Cost | 9/30/2013 Accumulated amortization | 9/30/2013 Net | 12/31/2012 Cost | 12/31/2012 Accumulated amortization | 12/31/2012 Net |
| Acquisition of interest - Goodwill | | **2,128,232** | **(153,831)** | **1,974,401** | 2,128,232 | (153,831) | 1,974,401 |
| Other intangible assets | | | | | | | |
| IT systems | 20 | **166,101** | **(99,976)** | **66,125** | 142,380 | (85,444) | 56,936 |
| Commercial area use right | 20 | **1,203** | **(609)** | **594** | 1,203 | (537) | 666 |
| Other intangible assets | 20 | **12,628** | **(4,481)** | **8,147** | 12,628 | (3,622) | 9,006 |
| System implementation project | 20 | **12,293** | **(12,293)** | **-** | 12,293 | (12,293) | - |
| Project development | 33 | **10,259** | **(10,259)** | **-** | 10,259 | (10,166) | 93 |
| Brands | 3.3 | **236,037** | **(21,007)** | **215,030** | 236,037 | (15,300) | 220,737 |
| Exclusive agreement with customers - Unimagem | 10 | **9,403** | **(4,469)** | **4,934** | 9,403 | (3,767) | 5,636 |
| Relationship with hospitals | 5 | **35,748** | **(5,547)** | **30,201** | 35,748 | (4,188) | 31,560 |
| | | **483,672** | **(158,641)** | **325,031** | 459,951 | (135,317) | 324,634 |
| | | **2,611,904** | **(312,472)** | **2,299,432** | 2,588,183 | (289,148) | 2,299,035 |

| | Consolidated | | | | | | |
|---|---|---|---|---|---|---|---|
| | Average amortization rate % p.a. | 9/30/2013 Cost | 9/30/2013 Accumulated amortization | 9/30/2013 Net | 12/31/2012 Cost | 12/31/2012 Accumulated amortization | 12/31/2012 Net |
| Acquisition of interest - Goodwill | | **2,206,183** | **(205,309)** | **2,000,874** | 2,206,183 | (205,309) | 2,000,874 |
| Other intangible assets | | | | | | | |
| IT systems | 20 | **172,173** | **(103,582)** | **68,591** | 147,885 | (88,254) | 59,631 |
| Commercial area use right | 20 | **1,359** | **(684)** | **675** | 1,359 | (612) | 747 |
| Other intangible assets | 20 | **14,018** | **(4,509)** | **9,509** | 14,018 | (3,634) | 10,384 |
| System implementation project | 20 | **12,293** | **(12,293)** | **-** | 12,293 | (12,293) | - |
| Project development | 33 | **10,267** | **(10,267)** | **-** | 10,267 | (10,210) | 57 |
| Brands | 3.3 | **251,663** | **(22,637)** | **229,026** | 251,663 | (16,441) | 235,222 |
| Exclusive agreement with customers - Unimagem | 10 | **9,403** | **(4,472)** | **4,931** | 9,403 | (3,767) | 5,636 |
| Relationship with hospitals | 5 | **40,488** | **(7,520)** | **32,968** | 40,488 | (5,597) | 34,891 |
| | | **511,664** | **(165,964)** | **345,700** | 487,376 | (140,808) | 346,568 |
| | | **2,717,847** | **(371,273)** | **2,346,574** | 2,693,559 | (346,117) | 2,347,442 |

### Changes in cost

| | Company | | | |
|---|---|---|---|---|
| | | Changes in the period | | |
| | 12/31/2012 | Additions | Transfer | 9/30/2013 |
| Acquisition of interest – Goodwill | 2,128,232 | **-** | **-** | **2,128,232** |
| Other intangible assets | | | | |
| IT systems | 142,380 | **23,251** | **470** | **166,101** |
| Commercial area use right | 1,203 | **-** | **-** | **1,203** |
| Other intangible assets | 12,628 | **-** | **-** | **12,628** |
| System implementation project | 12,293 | **-** | **-** | **12,293** |
| Project development | 10,259 | **-** | **-** | **10,259** |
| Brands | 236,037 | **-** | **-** | **236,037** |
| Exclusive agreement with customers – Unimagem | 9,403 | **-** | **-** | **9,403** |
| Relationship with hospitals | 35,748 | **-** | **-** | **35,748** |
| | 459,951 | **23,251** | **470** | **483,672** |
| | 2,588,183 | **23,251** | **470** | **2,611,904** |

## Notes to the quarterly information

| | Consolidated | | | |
|---|---|---|---|---|
| | | Changes in the period | | |
| | 12/31/2012 | Additions | Transfer | 9/30/2013 |
| Acquisition of interest – Goodwill | 2,206,183 | - | - | **2,206,183** |
| Other intangible assets | | | | |
| IT systems | 147,885 | **23,655** | **633** | **172,173** |
| Commercial area use right | 1,359 | - | - | **1,359** |
| Other intangible assets | 14,018 | - | - | **14,018** |
| System implementation project | 12,293 | - | - | **12,293** |
| Project development | 10,267 | - | - | **10,267** |
| Brands | 251,663 | - | - | **251,663** |
| Exclusive agreement with customers – Unimagem | 9,403 | - | - | **9,403** |
| Relationship with hospitals | 40,488 | - | - | **40,488** |
| | 487,376 | **23,655** | **633** | **511,664** |
| | 2,693,559 | **23,655** | **633** | **2,717,847** |

### Changes in accumulated amortization

| | Company | | |
|---|---|---|---|
| | | Changes in the period | |
| | 12/31/2012 | Amortization | 9/30/2013 |
| Acquisition of interest – Goodwill | (153,831) | - | **(153,831)** |
| Other intangible assets | | | |
| IT systems | (85,444) | (14,532) | **(99,976)** |
| Commercial area use right | (537) | (72) | **(609)** |
| Other intangible assets | (3,622) | (859) | **(4,481)** |
| System implementation project | (12,293) | - | **(12,293)** |
| Project development | (10,166) | (93) | **(10,259)** |
| Brands | (15,300) | (5,707) | **(21,007)** |
| Exclusive agreement with customers - Unimagem | (3,767) | (702) | **(4,469)** |
| Relationship with hospitals | (4,188) | (1,359) | **(5,547)** |
| | (135,317) | (23,324) | **(158,641)** |
| | (289,148) | (23,324) | **(312,472)** |

| | Consolidated | | |
|---|---|---|---|
| | | Changes in the period | |
| | 12/31/2012 | Amortization | 9/30/2013 |
| Acquisition of interest - Goodwill | (205,309) | **-** | **(205,309)** |
| Other intangible assets | | | |
| IT systems | (88,254) | **(15,328)** | **(103,582)** |
| Commercial area use right | (612) | **(72)** | **(684)** |
| Other intangible assets | (3,634) | **(875)** | **(4,509)** |
| System implementation project | (12,293) | **-** | **(12,293)** |
| Project development | (10,210) | **(57)** | **(10,267)** |
| Brands | (16,441) | **(6,196)** | **(22,637)** |
| Exclusive agreement with customers - Unimagem | (3,767) | **(705)** | **(4,472)** |
| Relationship with hospitals | (5,597) | **(1,923)** | **(7,520)** |
| | (140,808) | **(25,156)** | **(165,964)** |
| | (346,117) | **(25,156)** | **(371,273)** |

## Notes to the quarterly information

Additions to accumulated amortization, stated in changes for the period, were partly recorded under general and administrative expenses and partly under costs of goods and/or services sold.

During the quarter, the Company did not identify any assets impairment indicator.

## 15. Trade accounts payable

| | Company | | Consolidated | |
|---|---|---|---|---|
| | 9/30/2013 | 12/31/2012 | 9/30/2013 | 12/31/2012 |
| Domestic suppliers | **52,409** | 53,460 | **78,151** | 83,138 |
| Foreign suppliers | **380** | 1,254 | **411** | 1,291 |
| | **52,789** | 54,714 | **78,562** | 84,429 |

## 16. Loans and financing

| Type | Average rate | Final maturity | Company 9/30/2013 | Company 12/31/2012 | Consolidated 9/30/2013 | Consolidated 12/31/2012 |
|---|---|---|---|---|---|---|
| Local currency | | | | | | |
| Banco HSBC | 113.0% of CDI | 3/25/2013 | **-** | 1,251 | **-** | 1,251 |
| Banco do Brasil (iii) | 111.0% of CDI | 6/1/2015 | **-** | - | **23,815** | 28,669 |
| BNDES (ii) e (iii) | TJLP + 5.8% p.a. | 5/15/2016 | **-** | - | **-** | 3,117 |
| Sundry banks | 115.0% of CDI | 11/29/2012 | **-** | - | **-** | 70 |
| Financial lease – Sundry banks - Note 28 (i), (ii) and (iii) | CDI + 2.85% p.a. | 10/26/2015 | **5,296** | 8,246 | **19,148** | 30,801 |
| | | | **5,296** | 9,497 | **42,999** | 63,908 |
| Foreign currency | | | | | | |
| Financing of equipment (i), (ii) and (iii) | 7.10% p.a. | 12/1/2016 | **-** | - | **3,227** | 3,862 |
| Financial lease – Sundry banks - Note 28 (ii) and (iii) | 6.30% p.a. | 3/23/2016 | **9,935** | 18,655 | **11,762** | 21,387 |
| Credit Agricole Bank | 1.32% p.a. | 8/20/2014 | **-** | - | **67,003** | - |
| Senior Notes (a) (iii) | 8.75% p.a. | - | **-** | - | **-** | 59,652 |
| | | | **9,935** | 18,655 | **81,992** | 84,901 |
| Transaction cost – issue of notes (b) | | | **-** | - | **-** | (1,412) |
| | | | **15,231** | 28,152 | **124,991** | 147,397 |
| Current liabilities | | | **(10,939)** | (16,840) | **(97,658)** | (44,520) |
| Noncurrent liabilities | | | **4,292** | 11,312 | **27,333** | 102,877 |

The Company is not exposed to short-term refinancing risk.

Guarantors:

(i) DASA Real Estate Empreendimentos Imobiliários Ltda.

(ii) Promissory Note of 125% of contractual amount in the Company's name.

(iii) Diagnósticos da América S.A.

Bank loan and financing agreements do not have covenants.

(a) The Company's Board of Directors' meeting held on April 4, 2013 approved the execution by its wholly-owned subsidiary Dasa Finance Corporation, of its right to acquire the remaining issue notes of the acquisition announced on November 11, 2010 and completed on December 16, 2010. In addition, it authorized the management to adopt all the arrangements required to facilitate fund raising instruments that the Company's improve debt profile. Payment of amounts due to the holders of the Notes that joined the bid was held on August 30, 2013 and included the award of 4.875% as the indenture. With the acquisition, the Company informs that there is no remaining Notes to be acquired.

(b) The transaction cost amounts were appropriated to income on the repurchase date of Notes

Bank loans and financing classified as non-current liabilities, according to the contractual maturity dates, will be repaid as follows:

| | Company | Consolidated |
|---|---|---|
| 2014 (as from october 1) | 1,647 | 9,722 |
| 2015 | 2,574 | 17,097 |
| 2016 | 71 | 514 |
| | 4,292 | 27,333 |

The Company granted collaterals to its subsidiaries as follows:

| | | |
|---|---|---|
| CDPI - Clínica de Diagnóstico por Imagem Ltda. | Banco ABC Brasil | 4,521 |
| | General Eletric | 687 |
| | Banco Itaú S.A. | 2,478 |
| | Banco do Brasil | 5,000 |
| CientificaLab Produtos Lab. e Sistemas Ltda. | Banco Pottencial | 2,428 |
| DASA Finance Corporation | Emissão de Bond | 66,900 |
| Laboratórios Médicos Dr. Sérgio Franco Ltda. | Banco Itaú S.A. | 25,000 |
| | Banco do Brasil | 2,712 |
| Pro Echo Cardiodata Serviços Médicos Ltda. | General Eletric | 708 |
| | Banco Itaú S.A. | 1,099 |
| CRMI - Clínica de Ressonância e Multi Imagem Ltda. | Banco do Brasil | 4,000 |
| | | 115,533 |

## 17. Debentures (Company and consolidated)

| | 9/30/2013 | 12/31/2012 |
|---|---|---|
| Nonconvertible debentures | **950,000** | 950,000 |
| Compensatory interest | **37,457** | 13,239 |
| | **987,457** | 963,239 |
| Transaction cost | **(3,315)** | (4,255) |
| | **984,142** | 958,984 |
| Current | **(332,037)** | (74,485) |
| Noncurrent | **652,105** | 884,499 |

## Notes to the quarterly information

Deadline for amortization of the main value of second- and third-issue debentures is as follows:

| | |
|---|---|
| 10/25/2013 | 62,500 |
| 04/29/2014 | 233,333 |
| 10/25/2014 | 62,500 |
| 04/29/2015 | 233,333 |
| 10/25/2015 | 62,500 |
| 04/29/2016 | 233,334 |
| 10/25/2017 | 62,500 |
| | 950,000 |

2nd Issue

In the meeting held on March 16, 2011, the Board of Directors of the Company approved a fund raising by conducting the 2nd issue of simple debentures non-convertible into shares of the Company, for public distribution in the total amount of up to R$810,000, on a firm guarantee and better efforts of placement basis, under the terms of CVM Ruling No. 476 of January 16, 2009, as amended.

On May 16, 2011, the Company communicated to its shareholders and the market in general that on May 11, 2011, it closed the public offer for distribution with restricted placement efforts, of a single series of simple debentures non-convertible into shares, of the unsecured type. Seventy thousand 70,000 debentures were subscribed for a 5-year term from the date of issue, in the total amount of R$ 700,000. The debenture remuneration is equivalent to 100% of the accumulated variation of the Inter-financial Deposit (DI) daily average rates, “over extra-group”, expressed in percentage per annum and based on 252 working days, as calculated and daily disclosed by the Clearing House for the Custody and Financial Settlement of Securities (CETIP), plus an exponential surcharge of 1.40%. As the issue date was April 29, 2011, the face value of each debenture will be paid in 3 consecutive annual installments, as from the 36th month from the issue date. Payment of remuneration interest is semiannual, occurring on the 1st day of April and October, and the debit in the Company account shall occur one day prior to due date.

The transaction cost will be amortized up to April 2016, and totals R$ 3,315 at September 30, 2013 (R$4,255 at December 31, 2012).

3rd Issue

On October 15, 2012, the Board of Directors of the Company approved the third issue by the Company, of up to 25,000 debentures non-convertible into shares of the unsecured type, in a single series, in the total amount of up to R$250,000, for placement through a public offer with restricted efforts, pursuant to CVM Instruction No. 476 of January 16, 2009, as amended.

On November 1, 2012, the Company communicated to its shareholders and the market in general that on October 31, 2012 it had closed the public offer for distribution, with restricted placement efforts, of the third issue of DASA’s simple debentures non-convertible into shares, of the unsecured type, in one single series. Twenty-five thousand (25,000) debentures were subscribed for a 4-year term from the date of issue, in the total amount of R$ 250,000. The debentures are not subject to monetary adjustment, and the debit balance of each debenture face value will incur an interest equivalent to 100% of the accumulated variation of the Inter-financial Deposit (DI) daily average rates, “over extra-group”, expressed in percentage per annum and based on 252 working days, as calculated and daily disclosed by CETIP, plus a surcharge of 0.80% per annum, calculated based on 252 business days, exponentially and cumulatively, on a pro rata temporis basis, per business day elapsed from the Date of Issue or the payment date of the immediately prior remuneration, as the case may be, until the effective payment date.

## Notes to the quarterly information

Interest will be paid semiannually from the Issue Date, the first payment beginning on April 25, 2013 and the last payment to be made on the Maturity Date, without prejudice to payments resulting from early redemption of the Debentures, early repayment of the Debentures and/or prepayment of obligations arising out of the Debentures.

The face value of each Debenture will be repaid in 4 annual and successive installments, in the following order:

I. Three installments, each in the amount corresponding to 25% of the face value of each Debenture, due on October 25, 2013, October 25, 2014 and October 25, 2015; and

II. One installment in the amount corresponding to the outstanding balance of the face value of each Debenture, due on October 25, 2016.

The financial settlement of the offer occurred on October 31, 2012 in the amount of R$250,304, and the net proceeds of the offer were used towards (i) the early redemption of all commercial promissory notes of the third issue of the Company; and (ii) the balance to reinforce the working capital of the Company.

The debentures have clauses establishing maximum indebtedness and leverage ratios, based on the consolidated quarterly financial information, as detailed in Note 26. At the end of the period, the Company was in compliance with the contractual covenants, as follows:

| Indicator | Contractual terms (a) | Condition at 09/30/13 | Condition at 12/31/12 |
|---|---|---|---|
| EBITDA – Last 12 months (b) | | **404,130** | 407,577 |
| Financial income – Last 12 months | | **88,588** | 113,692 |
| Net debt | | **856,861** | 847,142 |
| 1- Net debt / EBITDA – maximum index | | | |
| 2ª Issuance | 2.50 | **2.12** | 2.08 |
| 3ª Issuance | 3.00 | **2.12** | 2.08 |
| 2- EBITDA / Financial income – minimum index | | | |
| 2ª Issuance | 2.00 | **4.56** | 3.58 |
| 3ª Issuance | 2.00 | **4.56** | 3.58 |

(a) The Company will be deemed to be in non-compliance with this covenant if it exceeds such ratios for two consecutive quarters.

(b) The information and EBITDA are not part of the scope of auditor's review work.

## 18. Social and labor liabilities

| | Company | | Consolidated | |
|---|---|---|---|---|
| | 9/30/2013 | 12/31/2012 | 9/30/2013 | 12/31/2012 |
| Salaries payable | **12,683** | 11,905 | **17,498** | 16,598 |
| Payroll charges payable | **10,356** | 10,963 | **13,939** | 14,991 |
| Accrual for vacation pay and social charges | **58,694** | 36,184 | **78,753** | 48,366 |
| Provision for profit sharing | **10,874** | - | **10,874** | - |
| Other | **1,460** | 357 | **1,788** | 1,236 |
| | **94,067** | 59,409 | **122,852** | 81,191 |

## Notes to the quarterly information

## 19. Taxes in installments

| | | Company | | Consolidated | |
|---|---|---|---|---|---|
| | Completion of amortization | 9/30/2013 | 12/31/2012 | 9/30/2013 | 12/31/2012 |
| PAES Program (a) | 2013 | **-** | 1,155 | **-** | 1,155 |
| REFIS IV - Federal (b) | 2020 | **9,672** | 10,113 | **19,161** | 21,208 |
| ICMS – RJ (c) | | **-** | - | **3,516** | 5,103 |
| ISS – CERPE (d) | | **-** | - | **2,816** | 2,429 |
| Other | | **894** | 1,124 | **2,813** | 2,935 |
| | | **10,566** | 12,392 | **28,306** | 32,830 |
| Current | | **(1,108)** | (2,370) | **(4,757)** | (4,820) |
| Noncurrent | | **9,458** | 10,022 | **23,549** | 28,010 |

(a) PAES (special program for tax payment)

On July 29, 2003, the Company joined the special program for tax payment in installments (PAES) – Law No. 10684 – and entered the tax debts related to PIS and COFINS that were being discussed in court. The consolidated debt was divided into 120 monthly installments and adjusted using the long term interest rate (TJLP), and amortizations were made until June 2013. In March 2013, the Company recorded the additional amount of R$ 2,767, to reflect the balance payable under PAES in the statement provided by the Brazilian IRS. From this amount, R$ 1,743, recorded under general and administrative expenses, refer to (i) debts from 1998 to 2001 of companies merged into the Company (Bronstein, Lâmina and Lavoisier), and (ii) fine on arrears reduced by 50%, having the Company previously discussed the unconstitutionality of such fine on tax debts related to PIS payable by the Company and COFINS payable by the merged Company (Lâmina), and the R$ 1,024 recorded in financial expenses refer to interest adjusted by TJLP applied to such debts consolidated by the Company in March 2013. Considering the payment of the final balance at June 30, 2013, there are no other amounts recorded in liabilities in connection with this PAES.

(b) REFIS IV – Special federal tax payment program – Law No. 11941/09

A new Installment program (REFIS IV) for federal Debts was created in connection with the enactment of Law No. 11941/09 comprising all debts under the Brazilian Federal Tax Authorities (Brazilian IRS, General Attorney's Office for the Treasury Department – PGFN and Brazilian Social Security Institute - INSS), either incorporated or not, included or not as federal enforceable debt, whether executed or not, including those which have been subject matter of a prior installment program. Given the favorable conditions of this new program, on November 27, 2009, the Company enrolled therewith, and made the first installment payment under the conditions stated in the legislation, and, monthly, through minimum installments paid up to the effective consolidation of the debt. The balance at September 30, 2013 is R$ 9,672 (R$ 10,113 at December 31, 2012) in Company, and R$ 19,161 at September 30, 2013 (R$ 21,208 at December 31, 2012) in consolidated.

The company also included in the installment program tax debts for which former partners/shareholders of the acquired companies were liable. Such debts have not been recorded under taxes in installments yet, because the review process with the former owners has not been concluded. This process should result in the redemption, proportional to the debts assumed by the prior management, of marketable securities used as guarantees for settlement of liabilities assumed at the time the companies were acquired (Note 8).

The term for consolidation of debts in the special installment plan for major taxpayers with differentiated monitoring ended on June 30, 2011. The Company has not concluded the consolidation yet, as information about debts originated from the companies acquired by the Company, which has already been merged, was not available on the Brazilian IRS website during the period of consolidation. The Company, aiming to ensure recognition of the acquired companies' debts in the installment program, has filed for petitions in the period between June 27 and 28, 2011 before the agencies handling debts subject to the installment plan, requiring such debts to be stated as entitled to inclusion in the installment payment on the E-CAC system. The Company has not yet received an answer to petitions filed.

(c) ICMS – RJ Payment in installments

Special tax debt payment in installments in Rio de Janeiro – Law 6.136/11

Rio de Janeiro State Law No. 6136/11, regulated by Rio de Janeiro State Decree No. 43443/12 and Resolution No. 3080/12 of Rio de Janeiro State General Prosecution Office, enacted a special program that provides for elimination of 100% of fines and 50% of interest on debts registered as Enforceable Tax Debt, authorizing payment thereof within 18 months or through offset against securities issued in connection with court ordered debts ("precatórios"), observing the limit of 95% of debts.

Considering these favorable conditions, the Company, through its subsidiaries Clínica de Ressonância e Multi-Imagem Ltda. (CRMI), Pro Echo Cardiodata Serviços Médicos Ltda. (Pro Echo) e CDPI – Clínica de Diagnóstico por Imagem Ltda. (CDPI), elected to use the benefits of Law, adhering to the program on 05/31/2012 and thus eliminating the tax contingencies related to ICMS on import recorded in provision accounts (Note 21).

The subsidiaries adhered to pay the debts through offset against securities issued, considering the limits established by Law , CDPI also opted for settling its debts in 18 monthly installments. At September 30, 2013, such debts balance was R$ 319 (R$ 570 at December 31, 2012).

On June 1, 2012, there was full payment of lawyers' fees related to debts in relation to which the Company opted for offset against securities issued in connection with court ordered debts. On the same date, there was payment of the first installment of debts payable in 18 monthly installments.

The modality of offset against securities issued in connection with court ordered debts depends on approval by the government department assisting the president ("Casa Civil") and, upon such approval, there shall be payment in cash of 5% of waived debts, which may not be offset against such securities, after being summoned by the State General Attorney's Office (PGE), under penalty of the offset to be considered invalid on the terms of article 10 of Law No. 6136/11. Only upon approval will the Company recognize in P&L the discount on the acquisition of the securities used to offset the debts.

The breakdown of the amounts included in the referred to special payment in installments, as well as of their settlement - offsetting against securities issued in connection with court ordered debts – is as follows:

| | **Total** | **Precatórios (securities)** | **In cash** |
|---|---|---|---|
| Clínica de Ressonância e Multi-Imagem Ltda. | 3,198 | 2,945 | 253 |

The net nominal amount of discount referring to the securities issued in connection with court ordered debts is recorded in Other noncurrent assets, and breaks down as follows:

| | Nominal value | Discount | Amount paid |
|---|---|---|---|
| Clínica de Ressonância e Multi-Imagem Ltda. | 2,945 | (960) | 1,985 |

(d) ISS payment in installments – CERPE

In 2009, subsidiary CERPE decided to use the benefits offered by Law No. 17384/2007 of Recife city, Pernambuco state. The referred Law provided benefits such as reduction of principal by 60%, in addition to total exemption from fines and interest referring to a number of ISS-related debts, which were subject to a previous special installment program, also granted by the Recife city administration. In addition to the above-mentioned benefits, the referred Law also allowed the Company to settle such debts in up to 240 (two hundred and forty) installments. Consequently, they will be fully paid by 2029. The debts balance at September 30, 2013 was R$ 2,816 (R$ 2,429 at December 31, 2012).

## 20. Accounts payable for acquisitions of subsidiaries

Accounts payable for acquisition of subsidiaries relate to the amounts due to their former owners upon the acquisition of shares or quotas representing the paid-in capital of these companies. Debts are restated in accordance with contractual clauses and have the following settlement schedules:

| | | | Company | | Consolidated | |
|---|---|---|---|---|---|---|
| | Restatement | Maturity | 9/30/2013 | 12/31/2012 | 9/30/2013 | 12/31/2012 |
| Not guaranteed by marketable securities | IPCA-IGPM-Selic | 05/2016 | **10,463** | 11,797 | **10,462** | 11,797 |
| Guaranteed by marketable securities | (a) | Nov/2016 and Apr/2017 | **27,672** | 46,803 | **39,079** | 57,635 |
| | | | **38,135** | 58,600 | **49,541** | 69,432 |
| Current | | | **(1,668)** | (1,598) | **(1,668)** | (1,598) |
| Noncurrent | | | **36,467** | 57,002 | **47,873** | 67,834 |

(a) Restated at the average rate of 102.07% of CDI (102.63% of CDI at December 31, 2012) for fixed-income funds, and 101.01% of CDI (100.00% of CDI at December 31, 2012) for CDB/ committed transactions, which are managed by financial entities, as shown in Note 8.

The installments classified as non-current liabilities have the following payment schedule:

| Aging list | Company | Consolidated |
|---|---|---|
| 2014 (as from October 1) | 335 | 335 |
| 2015 | 14,799 | 14,799 |
| 2016 | 21,218 | 28,470 |
| 2017 to 2020 | 115 | 4,269 |
| Total | 36,467 | 47,873 |

## 21. Provisions for tax, social security, labor and civil proceedings

| | Company | | | |
|---|---|---|---|---|
| | 9/30/2013 | | 12/31/2012 | |
| | Provision | Judicial deposit | Provision | Judicial deposit |
| ICMS on import (a) | **16,421** | **53,609** | 96,155 | 51,642 |
| Labor and civil contingencies (b) | **7,109** | **6,061** | 4,182 | 9,908 |
| Tax contingencies (c) | **28,745** | **32,310** | 28,589 | 29,567 |
| | **52,275** | **91,980** | 128,926 | 91,117 |

| | Consolidated | | | |
|---|---|---|---|---|
| | 9/30/2013 | | 12/31/2012 | |
| | Provision | Judicial deposit | Provision | Judicial deposit |
| ICMS on import (a) | **16,421** | **53,609** | 96,155 | 51,642 |
| Labor and civil contingencies (b) | **7,977** | **7,291** | 5,057 | 9,980 |
| Tax contingencies (c) | **31,195** | **35,851** | 31,039 | 33,652 |
| | **55,593** | **96,751** | 132,251 | 95,274 |

(a) ICMS on import

Following the opinion of its legal advisors, the Company has not paid ICMS on the import of inputs and equipment for use in the rendering of its services since February 2000, as there are ongoing discussions as to whether the Company is an ICMS taxpayer for these transactions. For ICMS payables on goods and equipment imported up to the publication of Constitutional amendment 33 on December 11, 2001, the external legal advisors understand that the likelihood of losses is remote; as regarding to ICMS payables generated between the Constitutional Amendment 33 date and the issuance of the supplementary Law No. 114, on December 16, 2002, the likelihood of loss was classified as possible. For import of equipment under the lease modality, the likelihood of loss was also deemed as possible. Finally, after enactment of the supplementary Law No. 114 on December 16, 2002, the external legal advisors understand that the likelihood of loss is probable.

The São Paulo State Decree No. 58811/12 created a special installment program ("PEP of ICMS/SP"), in which companies may enroll until August 31, 2013, and that established the exclusion of up to 75% of fines and of up to 50% of interest related to ICMS debts, either incorporated or not, including those deemed as federal enforceable debt, whether executed or not, and referring to tax triggering events occurring until July 31, 2012. Debts subject to tax delinquency notice and imposition of fine (AIIM), and which are not federal enforceable debts, are entitled to additional fine deductions.

Given these favorable conditions, the Company decided to use the benefits offered by the PEP of ICMS/SP and joined the program in May 2013, which includes the ICMS debts on direct import of equipment and input carried out between 2007 and 2011, which have not been object of a tax delinquency notice yet, but are an object of a writ of mandamus issued by the São Paulo State Court. The payment in cash was made on May 22 and June 5, 2013, totaling R$ 39,398, as shown in the table below:

*Mandamus issued Nº 0046827-27.2011.8.26.0053*

| ICMS Debits (Not Reductions)Débitos de ICMS (sem reduções) | Reductions of PEP | Debits after PEP Reductions PEP | Existent provision | Profit obtained |
|---|---|---|---|---|

## Notes to the quarterly information

| | | | | |
|---|---|---|---|---|
| **55,286** | **(15,888)** | **39,398** | **48,726** | **(9,328)** |

## Notes to the quarterly information

Consequently, considering that there was a previously set-up provision for contingencies for the referred to debts in the amount of R$ 48,726, final gains arising out of PEP was R$ 9,328. This amount was recognized in financial income for the period.

Considering that the Company decided to pay in cash, there are no longer amounts recorded under liabilities in connection with the special installment payment program related to non-notified ICMS debts on import.

On August 23, 2013, the Company also included in PEP part of State VAT (ICMS)-import debts subject to Tax Delinquency Notice – AIIM No.3091324-8, of April 30, 2008. The aforesaid AIIM has ICMS debts levied on direct imports and international leases. The Company decided to include only debts related to direct imports for purposes of PEP, thus lease debts still remain subject to administrative procedure discussion.

The settlement in cash was made on September 3, 2013 in the amount of R$ 30.104, as under:

*AIIM Nº 3.091.324-0*

| ICMS Debts (Not reductions) | Reductions of PEP | Debits after PEP reductions | Existent provision | Profit obtained |
|---|---|---|---|---|
| **57,451** | **(27,348)** | **30,103** | **32,788** | **(2,685)** |

Accordingly, considering the provision for contingencies previously set up for debts related to AIIM No.3.091.324-0 in the amount of R$32,788, the final gain obtained in joining the PEP program totaled R$2,684, which was recognized in the income statement for the period.

After the Company opted for the cash payment, there were no longer amounts recorded under liabilities related to special installment payment made for ICMS debts on direct imports contained in the AIIM No.3.091.324-0.

The legal deadline to join PEP ended on August 31, 2013, the table below summarizes the total amounts subject to Company:

*Total*

| ICMS Debits (Not reductions) | Reductions of PEP | Debits after PEP reductions | Existent provision | Profit obtained |
|---|---|---|---|---|
| **112,737** | **(43,236)** | **69,501** | **81,514** | **(12,013)** |

Total amounts joined to PEP by the Company decreased the provision for contingencies, generating a gain of R$ 12,013, which was recognized in the income statement for the period. The remaining balance as at September 30, 2013 is amounted to R$81,514.

Because the Company joined the PEP program, which covered all tax debts guaranteed by judicial deposits, it requested a court assessment of such amount in December 2011. The judicial deposit made in December 2011 amounted to R$ 46,068, and the balance as of September 30, 2013 is amounted to R$ 53,609 (R$ 51,642 at December 31, 2012) concerning ICMS amounts collected on direct imports of inputs and equipment cleared through customs in the state of São Paulo, not subject to tax notice, claiming the right to settle the tax by voluntary payment, not subject to fine and with interest reduction, maintaining the calculation criteria of amounts for provision for losses. The lower court decision was partially favorable to the Company in the sense of recognizing the arguments presented for the collection of interest, however it rejecteded the claim presented by the Company related to the fine.

## Notes to the quarterly information

At September 30, 2013, the provision for import carried out since January 1, 2003 is R$ 16,421 (R$ 96,155 at December 31, 2012) in Company and consolidated

## Notes to the quarterly information

(b) Provision for labor and civil contingencies

At September 30, 2013, the Company is party to 1,229 labor claims (916 at December 31, 2012) and 1,144 civil administrative proceedings and lawsuits (893 at December 31, 2012). Provisions of R$ 7.109 (R$ 4,182 at December 31, 2012) in the Company and R$ 7,977 (R$ 5,057 at December 31, 2012) in the consolidated, are based on the historical percentage of loss of claims whose likelihood of an unfavorable outcome had been rated as probable. At September 30, 2013, the Company presents the consolidated amount of R$ 72,019 (R$ 78,570 at December 31, 2012) related to the claims classified by its legal advisors as possible loss, from which R$ 18,310 refers to civil claims and R$ 53,709 to labor claims for which there are no provisions, according to the accounting rule applicable for those circumstances.

The Company is also a party to a lawsuit for indemnification for loss of profits and pain and suffering due to supposed competition-related infraction by the Company together with a health insurance Company. An opposition was filed against the case amount against which claimants filed a reply, as such, an expert accounting and engineering examination was ordered. On December 7, 2007, the amount attributed to the case by claimant is R$ 61,815, which unfavorable outcome was classified as possible, and the amount involved has not been evaluated. An expert accounting examination conducted by the court expert concluded that the claimed loss of profit sought should amount to R$ 4,500, applicable to the health plan insurance Company.

From the amount of R$ 53,709 corresponding to labor claims classified as possible loss, we should mention the Public Civil Action at the Rio de Janeiro Labor Court, to which the Company and its subsidiary Laboratórios Médicos Dr. Sérgio Franco Ltda. are a party. In general, questioning the legality of the arrangements with health companies specialized in diagnostic support services by imaging, which required hiring doctors under the Consolidation of Labor Laws (CLT) and a collective indemnification for pain and suffering of approximately R$ 20,000 on September 10, 2012. The Company believes that, considering their specific characteristics, the arrangement principles which is being adopted, in addition to being in regular and in strict compliance with applicable laws, are supported by favorable former court decisions, and are in line with the disclosures and explanations reported in the Reference Form, in items 4.1 and 4.3. On October 29, 2012, the Company disclosed the foregoing as a “Material News Release”, pursuant to CVM Ruling No. 358 of January 2002. A hearing was held on February 20, 2013, and it was adjourned sine die.

(c) Provision for tax contingencies

The provisions for tax contingencies in the amount of R$ 28,745 (R$ 28,589 at December 31, 2012) in Company, and R$ 31,195 (R$ 31,039 at December 31, 2012) in consolidated, relate to: (i) questionings for increases in rates; (ii) calculation base; and (iii) unconstitutionality of collection. Such questionings refer basically to PIS, COFINS, INSS and FGTS contributions. At September 30, 2012, the Company recorded a consolidated amount of R$ 264,914 (R$ 218,210 at December 31, 2012), related to claims classified by its legal advisors as possible loss, for which there were no provisions, according to the accounting rule applicable for those circumstances, and substantially R$ 170,833 was related to ICMS claims (Taxes) over import of leasing equipment and direct import of inputs and equipment performed between the EC33 (issued in December 2001) and the Supplementary Law No. 114 (issued in December 2002), and R$ 94,081 related to other PIS, COFINS, IRPJ and ISS tax claims.

## Notes to the quarterly information

Changes in provisions for contingencies

| | Company | | | | |
|---|---|---|---|---|---|
| | 12/31/2012 | Change for the period | | | |
| | Closing balance | Additions to provision | Use and reversal | Restatement | Closing balance |
| ICMS on import | 96,155 | **-** | **(81,514)** | **1,780** | **16,421** |
| Provision for labor and civil contingencies | 4,182 | **10,383** | **(7,456)** | **-** | **7,109** |
| Provision for tax contingencies | 28,589 | **4** | **(179)** | **331** | **28,745** |
| | 128,926 | **10,387** | **(89,149)** | **2,111** | **52,275** |

| | Consolidated | | | | |
|---|---|---|---|---|---|
| | 12/31/2012 | Change for the period | | | |
| | Closing balance | Additions to provision | Use and reversal | Restatement | Closing balance |
| ICMS on import | 96,155 | - | (81,514) | 1,780 | 16,421 |
| Provision for labor and civil contingencies | 5,057 | 10,383 | (7,463) | - | 7,977 |
| Provision for tax contingencies | 31,039 | 4 | (179) | 331 | 31,195 |
| | 132,251 | 10,387 | (89,156) | 2,111 | 55,593 |

## 22. Equity

a) Share-based payment

At December 7, 2010, the board of directors approved a new stock option plan for our management and employees ("New Plan") and its chief guidelines were then determined on December 16, 2010.

The New Plan was approved at the Special General Meeting held on January 5, 2011. On the same date, a meeting of the board of directors approved the granting of shares under the New Plan and the first stock option program which, among other matters, elected the beneficiaries.

On May 9, 2011, the board of directors approved the election of the beneficiaries of the New Plan, and subject to the terms and conditions determined in the first program, the executive board signed stock option agreements with each of the beneficiaries.

Each beneficiary, having met the conditions stated for the plan will be granted options to acquire or subscribe to a number of registered common shares with no par value corresponding to the percentage of 250% (two hundred and fifty per cent) of own shares (acquired by the beneficiaries). Percentages for each individual beneficiary are defined by the board of directors and stated in the agreement signed with each beneficiary.

Other than the amount invested by the beneficiary for acquisition of treasury shares no other consideration shall be required of the beneficiary to exercise the benefit, and the above price consubstantiates the beneficiary's obligation to acquire the own shares and hold them for a period of three (3) years after acquiring them.

## Notes to the quarterly information

Stock options may only be exercised by beneficiaries, in full or in part, three (3) full years after the date of signing the agreement (vesting period).

At the end of the vesting period, beneficiaries may exercise their rights in full or in part by giving written notice to the Company within thirty (30) days of the vesting date, subject to specific requirements, dates and periodicities established by the board of directors.

*Stock options granted in May 2011*

In May 2011, the Executive Board entered into stock-option agreements with beneficiaries under the plan.
The number of shares initially granted was 309,076 common shares, currently 106,576 (114,775 at December 31, 2012) common shares granted considering the contracts canceled up to September 30, 2013, with Vesting Period until May 2014.

The September 30, 2013 balance recorded under Granted options, in equity, is R$ 979 (R$ 814 at December 31, 2012), equivalent to 83.806 (61,660 at December 31, 2012) common shares, corresponding to the total number of shares granted proportionally to the period incurred in the contracts executed, as follows:

| | Common shares | R$ |
|---|---|---|
| Balance at December 31, 2012 | 61,660 | 814 |
| Cancellations | **(4,701)** | **(64)** |
| Additions | **26,847** | **229** |
| Balance at September 30, 2013 | **83,806** | **979** |

*Share-based payment transactions – June 2012*

In June 2012, the Executive Board and the beneficiaries of the plan entered into option agreements for the acquisition of shares. The number of shares initially granted was 259,959 common shares, currently 212.465 (240,216 at December 31, 2012) common shares granted considering the contracts canceled up to September 30, 2013, with Vesting Period until June 2015.

The September 30, 2013 balance recorded under Other Payables, in equity, is R$ 1,048 (R$ 547 at December 31, 2012), equivalent to 89.725 (41,500 at December 31, 2012) common shares, corresponding to the total number of shares granted proportionally to the period incurred in the contracts executed, as follows:

| | Common shares | R$ |
|---|---|---|
| Balance at December 31, 2012 | 41,500 | 547 |
| Cancellations | **(8,789)** | **(104)** |
| Additions | **57,014** | **605** |
| Balance at September 30, 2013 | **89,725** | **1,048** |

## Notes to the quarterly information

b) Dividends and interest on equity

On June 20, 2013, the Company paid R$ 20,503 in dividends to shareholders, which was approved in the Annual Shareholders' Meeting held on April 22, 2013.

c) Earnings per share

*Basic*

Basic earnings per share is calculated by dividing income attributable to shareholders by the weighted average number of common shares issued during the period, excluding common shares purchased by the Company and held as treasury shares.

| | 01/01/2013 to 09/30/2013 | 01/01/2012 to 09/30/2012 |
|---|---|---|
| Profit attributable to Company's controlling shareholders | **94,591** | 86,596 |
| Weighted average number of issued common shares | **311,803** | 311,803 |
| Weighted average number of treasury stock | **(1,159)** | (1,159) |
| Weighted average number of outstanding common shares | **310,644** | 310,644 |
| Net earnings per share - R$ | **0.30450** | 0.27876 |

| | 07/01/2013 to 09/30/2013 | 07/01/2012 to 09/30/2012 |
|---|---|---|
| Profit attributable to Company's controlling shareholders | **35,910** | 26,945 |
| Weighted average number of issued common shares | **311,803** | 311,803 |
| Weighted average number of treasury stock | **(1,159)** | (1,159) |
| Weighted average number of outstanding common shares | **310,644** | 310,644 |
| Net earnings per share - R$ | **0.11560** | 0.08674 |

*Diluted*

Diluted earnings per share are calculated by adjusting the weighted average number of common shares outstanding assuming conversion of all common shares that could lead to dilution. The only common shares that could lead to dilution are from stock option plans, as disclosed in item (a) in this Note.

| Year to date | 01/01/2013 to 09/30/2013 | 01/01/2012 to 09/30/2012 |
|---|---|---|
| Profit attributable to Company's controlling shareholders | **94,591** | 86,596 |
| Weighted average number of outstanding common shares | **310,644** | 310,644 |
| Adjustment per stock option | **319** | 73 |
| Weighted average number of common shares per diluted earnings per share | **310,963** | 310,717 |
| Diluted earnings per share - R$ | **0.30419** | 0.27870 |

| Year to date | 07/01/2013 to 09/30/2013 | 07/01/2012 to 09/30/2012 |
|---|---|---|
| Profit attributable to Company's controlling shareholders | **35,910** | 26,945 |
| Weighted average number of outstanding common shares | **310,644** | 310,644 |
| Adjustment per stock option | **319** | 73 |
| Weighted average number of common shares per diluted earnings per share | **310,963** | 310,717 |
| Diluted earnings per share - R$ | **0.11548** | 0.08672 |

**Notes to the quarterly information**

## 23. Income and social contribution taxes

The company records monthly provisions for income and social contribution taxes on an accrual basis

Taxes are calculated by taxable income, except for subsidiaries Imagem e Diagnóstico, Multimagem PET and Multi-Imagem Petrópolis, in which it adopted the presumed profit system.

Reconciliation of the expense calculated by applying combined rates for income and social contribution tax expenses charged to income is shown as follows:

| | Company | | Consolidated | |
|---|---|---|---|---|
| | **9/30/13** | **9/30/12** | **9/30/13** | **9/30/12** |
| Income before income and social contribution | **125,031** | 106,000 | **148,326** | 131,808 |
| Combined tax | **34%** | 34% | **34%** | 34% |
| Income and social contribution At the combined | **(42,511)** | (36,040) | **(50,531)** | (44,815) |
| **Permanent exclusions (additions)** | | | | |
| Equity pickup | **14,732** | 18,494 | **-** | - |
| Interest on equity | **(1,274)** | (1,891) | **-** | - |
| Non-deductible | **(1,153)** | (364) | **(1,343)** | (522) |
| **Other adjustments** | | | | |
| Income (loss) from subsidiary in foreign | **-** | - | **(4,211)** | (1,116) |
| Taxable profit based on percentage of gross | **-** | - | **1,224** | 499 |
| Dasa Brasil | **-** | - | **1,146** | - |
| Other | **(234)** | 397 | **13** | 473 |
| | **(30,440)** | (19,404) | **(53,602)** | (45,481) |
| **Income and social contribution taxes –** | **-** | - | | |
| - Current | | | **(26,930)** | (24,075) |
| - Deferred taxes | **(30,440)** | (19,404) | **(26,672)** | (21,406) |
| - Total | **(30,440)** | (19,404) | **(53,602)** | (45,481) |
| Effective tax rate | **-24%** | -18% | **-36%** | -35% |

The 34% combined tax rate used for 2013 and 2012 calculations applies to taxable profit for legal entities in Brazil as required by the tax laws of this jurisdiction.

a) Deferred taxes on tax losses and temporary provisions

Income and social contribution taxes are stated so as to reflect future tax effects attributable to temporary differences between the assets and liabilities tax bases and their respective book values.

In accordance with CPC 32, based on the expectation of generating future taxable profit backed by a technical study approved by our management, the Company recognizes tax credits and debits on deductible temporary differences and accumulated tax losses and negative bases for social contribution, which are not subject to limitation and may be used to offset up to 30% of annual taxable profit. The book value for deferred tax assets and liabilities is reviewed quarterly and projections are reviewed annually.

The composition of the balances of deferred income and social contribution taxes assets and liabilities are shown below:

## Notes to the quarterly information

| | Balance sheet Company | | Income (loss) Company |
|---|---|---|---|
| | **9/30/13** | **12/31/12** | **9/30/13** |
| Income and social contribution tax losses | **146,914** | 98,246 | **48,668** |
| Allowance for doubtful accounts and disallowances | **19,795** | 25,074 | **(5,279)** |
| Goodwill amortization | **-** | 997 | **(997)** |
| Provision for specialized medical services | **10,126** | 3,757 | **6,369** |
| Sundry provisions | **3,914** | 168 | **3,746** |
| Provision for contingencies | **12,792** | 33,941 | **(21,149)** |
| Amortization of pre-operating expenses | **82** | 329 | **(247)** |
| Other | **680** | 514 | **166** |
| Goodwill amortization | **(172,424)** | (108,073) | **(64,351)** |
| Intangibles identified in acquisitions | **(85,119)** | (87,697) | **2,578** |
| Review of property and equipment useful lives | **(11,944)** | (9,154) | **(2,790)** |
| Outros | **(793)** | (3,640) | **2,847** |
| **Deferred income and social contribution taxes - Assets / (Liabilities)** | **(75,977)** | (45,538) | **-** |
| **Revenue (expenses) from income and social contribution - deferred** | **-** | - | **(30,439)** |
| **Reflected in the balance sheet as follows:** | | | |
| Deferred tax assets | | | **-** |
| Deferred tax liabilities | **(75,977)** | (45,538) | |
| **Deferred income and social contribution taxes - Assets /(Liabilities)** | **(75,977)** | (45,538) | |

| **Reconciliation of tax assets (liabilities) - deferred** | **9/30/13** |
|---|---|
| Balance at December 31, 2012 | **(45,538)** |
| Income / (expenses) from taxes recognized in income (loss) | **(30,449)** |
| **Balance September 30, 2013** | **(75,977)** |

| | Balance sheet Consolidated | | Income (loss) Consolidated |
|---|---|---|---|
| | **9/30/13** | **12/31/12** | **9/30/13** |
| Income and social contribution tax losses | **184,233** | 124,801 | **59,432** |
| Allowance for doubtful accounts and disallowances | **26,183** | 30,884 | **(4,701)** |
| Goodwill amortization | **20,962** | 28,297 | **(7,335)** |
| Provision for specialized medical services | **13,103** | 6,339 | **6,764** |
| Sundry provisions | **4,011** | 214 | **3,797** |
| Provision for contingencies | **13,785** | 34,935 | **(21,150)** |
| Amortization of pre-operating expenses | **82** | 329 | **(247)** |
| Other | **680** | 514 | **166** |
| Goodwill amortization | **(173,516)** | (109,124) | **(64,392)** |
| Intangibles identified in acquisitions | **(90,684)** | (93,429) | **2,745** |
| Remeasurement of useful life of property and equipment | **(9,155)** | (6,173) | **(2,982)** |
| Other | **(6,483)** | (7,715) | **1,232** |
| **Deferred income and social contribution taxes - Assets/ (Liabilities)** | **(16,799)** | 9,872 | |
| **Revenue (expenses) from income and social contribution taxes - deferred** | | | **(26,671)** |
| **Reflected in the balance sheet as follows:** | | | |
| Deferred tax assets | **59,178** | 57,002 | |
| Deferred tax liabilities | **(75,977)** | (47,130) | |
| **Deferred income and social contribution taxes - Assets/ (Liabilities)** | **(16,799)** | 9,872 | |

| **Reconciliation of deferred tax assets (liabilities)** | **9/30/13** |
|---|---|
| Balance at December 31, 2012 | **9,872** |
| Income / (expenses) from taxes recognized in income (loss) | **(26,671)** |
| Other | |
| **Balance at September 30, 2013** | **(16,799)** |

**Notes to the quarterly information**

Management believes that the balances of deferred income and social contribution tax assets on temporary differences will be realized in proportion to the contingencies and occurrence of the events that gave rise to the provisions for losses.

## 24. Cost of services provided

| | Company | | Consolidated | |
|---|---|---|---|---|
| | 9/30/2013 | 9/30/2012 | 9/30/2013 | 9/30/2012 |
| Personnel | **252,868** | 235,053 | **355,662** | 337,984 |
| Material | **214,603** | 201,324 | **327,589** | 306,755 |
| Services and utilities | **378,103** | 325,752 | **496,074** | 423,410 |
| Depreciation costs | **57,552** | 47,778 | **75,024** | 66,250 |
| General expenses | **13,284** | 11,897 | **19,115** | 16,242 |
| | **916,410** | 821,804 | **1,273,464** | 1,150,641 |

## 25. General and Administrative Expenses by nature

| | Company | | Consolidated | |
|---|---|---|---|---|
| | 9/30/2013 | 9/30/2012 | 9/30/2013 | 9/30/2012 |
| Personnel expenses | **125,829** | 116,888 | **168,255** | 160,270 |
| Provision for profit sharing and bonus | **19,557** | - | **21,422** | - |
| Services and utilities | **46,372** | 56,729 | **72,036** | 87,031 |
| Advertising and publicity | **7,183** | 4,824 | **8,454** | 5,722 |
| Freight costs | **25,476** | 20,449 | **29,249** | 22,571 |
| Depreciation and amortization | **37,685** | 36,159 | **40,800** | 44,178 |
| Taxes and charges | **2,965** | 826 | **5,011** | 1,611 |
| Sundry provisions | **9,970** | 2,769 | **11,136** | 232 |
| General expenses | **15,276** | 14,830 | **24,736** | 23,841 |
| | **290,313** | 253,474 | **381,099** | 345,456 |

## 26. Financial instruments

The Company is generally exposed to the following operating risks that may affect its strategic and financial objectives to a greater or lesser extent:

- Market risk
- Liquidity risk
- Credit risk
- Operating risk

The Company manages the risks to which it is exposed by defining conservative strategies to ensure liquidity, profitability, and security, using objective criteria for risk diversification.

This note reports the Company's exposure to each of the above risks, and its objectives, policies and processes for risk measurement and management and for capital management.

## Notes to the quarterly information

Risk management structure

In alignment with current regulations and with the Company's corporate policies, the system is based on the integrated management of each of the business processes and on adjusting risk level to strategic objectives. The Company's corporate governance structure involves an extensive risk management process for identifying, treating, and monitoring these risks that extends from senior management, and institutional committees such as the auditing committee, which is responsible, among other duties, for overseeing the integrity and effectiveness of internal controls and risk management through to all the Company's different areas.

The Company's internal control environment has been designed to support the nature, risk, and complexity of its operations. It is based on formalized policies and procedures that are disseminated throughout the organization, as well as dedicated business areas and specific tools for risk monitoring.

Management of all risks inherent to the Company's activities on an integrated basis is addressed within a process supported by the structures of Internal Controls and Compliance (in relation to internal policies, rules, and regulations) that ensures continuous improvement for risk management models and minimizes any omission that could jeopardize correct risk identification and assessment. Based on identification, assessment and monitoring of the principal risks, the Company draws up specific action plans to ensure that improvements are implemented.

To build the right control environment for the scale of its business, the Company invests to strengthen internal communication and disseminate the risk management concept among employees. Corporate risk management is supported by statistical tools with liability adequacy testing, stress testing, capital sufficiency indicators and others. In addition to these tools, the Company adds the qualitative side of risk management, with results from self-assessment, quality evaluations, and tests conducted by internal auditing to evaluate the effectiveness and efficiency of internal controls, as well as quality performance in fulfilling duties and responsibilities.

Historically, the financial instruments used by the Company have shown adequate results for risk mitigation. Additionally, we avoid transactions involving exotic or speculative derivatives.

*Market risks*

These are risks related to assets and liabilities with cash flows or present values that are exposed to:

a) *Exchange-rate risk*: Risk of loss or gain depending on fluctuations in prices of foreign currencies. The main tool to control exchange-rate related risk is the daily treasury position, which is based on reports provided by the BM&FBovespa and other sources (e.g. the Central Bank) for the control of exchange-rate variations involved in our operations.

b) *Market risk - interest*: Risk of fluctuating interest rates leading to increased expenses or decreased income. Fixed interest rates maintained to maturity allow certainty for cash flows. Floating interest rates pose volatility for future interest charges. The main tool for control of risk related to interest rates is the daily treasury position, which is based on reports provided by the BM&FBovespa to control interest rates involved in our transactions.

   Our principal market risks arise from possible fluctuations in interest rates and exchange rates. As a result, the Company and its subsidiaries seek hedging for liquidity risk through financial instruments such as marketable securities, funding in the form of working capital loans, and funding through the issue of debentures, all on an arms' length basis, as well as USD-CDI index swaps.

The Company's market risk management practices are based on the operating strategies and internal controls established in its Internal Policy for Risk Management of Financial Assets ("Policy") in order to ensure liquidity, profitability, and security of financial instruments exposed to risk. These practices consist of periodically monitoring its contractual conditions in comparison with current market conditions.

Every financial transaction is submitted to the Executive Committee and subsequent validation by the board of directors and / or their auxiliary advisory committees. In the cases of exchange rate and interest-rate exposure, guidelines are set by the board of directors and operated by the Treasury department, since they depend of variable components of the economic scenario. Treasury forwards a monthly report to the Executive Committee showing the Company's current exposure to market risks and using reports, documents and contracts checks for compliance with the policy.

In addition to the above, for market risks to which the Company is exposed, Treasury is mandated to run monthly stress tests assuming 25% and 50% variations in relation to original parameters in order to assess the elasticity of these positions when subjected to major variations of the rates involved in these transactions, and their impact on income and cash positions of the Company.

*Liquidity risk*

Liquidity risk is the risk of an unforeseeable event or an error in calculating liquidity requirements that will impact the Company's investment decisions or day-to-day business.

We manage liquidity risk by maintaining adequate reserves, bank credit facilities, and credit lines from funding as deemed appropriate, continuously monitoring expected and actual cash flows and the combination of maturity profiles of financial assets and liabilities, following these guidelines:

(a) Short-term cash management - liquid assets and credit facilities to cover immediate needs. Periodicity: Daily. Periodicity: D+1 (working days);

(b) Long-term cash management - Continuous process to ensure long-term funds, through analysis of the cash budget on a monthly basis, updating assumptions made in the budget in accordance with business needs, and comparing actual *versus* estimated performance. Periodicity: Monthly. Term: 5th working day of the month following the report's base date;

(c) Maintenance of minimum cash - Refers to cash balances the Company may replenish in a very short period of time to meet any urgent requirements. In addition, it uses the criterion that cash holdings must be sufficient to cover the five worst daily cash flows in a month, not including receivables;

(d) Exposure limits and risk mitigation - the treasury department keeps short-term facilities for immediate liquidity and working capital lines, so that volume is sufficient to ensure at least the amount equal to that of the highest cash outflow over five consecutive days in the last 12 months.

For medium and long term credit lines, the Treasury department maintains credit lines compatible with the Company's strategic planning, for the purpose of ensuring the availability of resources to meet the estimated cash flow.

## Notes to the quarterly information

The table below details the aging list of the consolidated financial liabilities at September 30, 2013:

| Transaction | Consolidated | | | | |
|---|---|---|---|---|---|
| | Up to 1 year | 1 to 2 years | 3 to 5 years | Over 5 years | Total |
| Derivatives | 126 | 12 | 25 | - | 163 |
| Trade accounts payable | 78,562 | - | - | - | 78,562 |
| Bank loans and financing | 97,658 | 9,722 | 17,611 | - | 124,991 |
| Debentures | 332,037 | 62,187 | 589,918 | - | 984,142 |
| Taxes in installments | 4,757 | 6,669 | 4,879 | 12,001 | 28,306 |
| Payables for acquisition of subsidiaries | 1,668 | 335 | 43,269 | 4,269 | 49,541 |
| | 514,808 | 78,925 | 655,702 | 16,270 | 1,265,705 |

*Credit risk*

Refers to the risk of loss resulting from inability of the counterparty to meet its contractual obligations and make payments to the Company. The principal means of mitigating this risk is through the credit analysis process. Measurement of credit risk over time will be based mainly on the determination of the allowance for doubtful accounts.

The Company and its subsidiaries are subordinated to the credit policy set by its management and their purpose is to minimize any problems deriving from default due to disallowances under plans. The Company also set up an allowance for doubtful accounts due to disallowances, default and returned checks in the Company amounting to R$ 58,221 (R$ 91,991 at December 31, 2012) representing 12,43% (20.59% at December 31, 2012) from the balance of outstanding receivables in order to cover credit risk, and in Consolidated R$ 77,285 (R$ 109,220 at December 31, 2012) representing 11,54% (17.97% at December 31, 2012) from the balance outstanding receivables in order to cover the credit risk.

At September 30, 2013, the maximum exposure in consolidated was R$ 892,601 (R$ 836,194 at December 31, 2012) referring to cash and cash equivalents and receivables.

*Operating risk*

Operating risk is the risk of direct or indirect loss arising from a variety of causes associated with our personnel, technology and infrastructure processes, as well as external factors, other than credit, market and liquidity risks. It includes risks such as those arising from legal and regulatory requirements and generally accepted standards of corporate conduct. Operating risks arise from all our operations.

The objective of the Company is to manage operating risk to prevent the occurrence of financial losses or damage to its reputation while ensuring cost effectiveness and avoiding control procedures that hamper initiative and creativity.

The primary responsibility for developing and implementing controls to cover operating risk is attributed to senior management. The latter is supported by development of overall standards for operating risk management in the following areas:

- Requirements for appropriate segregation of duties, including independent authorization of transactions;

- Requirements for reconciliation and monitoring transactions;

## Notes to the quarterly information

- Compliance with legal and regulatory requirements
- Documentation of controls and procedures;
- Requirements for periodic assessment of operating risks faced, and adequacy of controls and procedures to treat the identified risks;
- Requirements for reporting transaction losses and proposed corrective measures;
- Developing contingency plans;
- Professional training and development;
- Ethical and business standards;
- Risk mitigation, including insurance, when effective

Compliance with the Company's rules is supported by a continuous quality assessment process and a program for periodical analysis of the Internal Auditing responsibilities. The results of the Internal Auditing analyses are discussed with the management of the related business unit, and reports are sent to the Auditing Committee and to the Company management.

*Capital management*

The Company monitors the financial leverage to maintain an appropriate capital structure for the operation and to reduce the indebtedness cost. The leverage ratio used corresponds to net debt divided by total equity.

The consolidated levels of financial leverage ratios at September 30, 2013 and December 31, 2012 are broken down as follows:

| | 9/30/2013 | 12/31/2012 |
|---|---|---|
| Loans and financing (a) | **124,991** | 147,397 |
| Debentures (a) | **984,142** | 958,984 |
| Derivative financial instruments | **163** | 1,233 |
| Total gross debt | **1,109,296** | 1,107,614 |
| Cash and cash equivalents and marketable securities – current assets | **(252,435)** | 260,472 |
| Net debt | **856,861** | 847,142 |
| Equity | **2,702,313** | 2,607,192 |
| Contents | **0.31708** | 0.32493 |

(a) Amounts are reported net of transaction costs

The Company may alter its capital structure depending on economic-financial, strategic or operational conditions, in order to improve debt management. At the same time, it aims to improve return on invested capital (ROIC) through working capital management and an efficient investment program.

The Company is subject to maximum indebtedness levels according to the terms presented in Note 17.

## Notes to the quarterly information

Financial instrument by category

The table below shows the Company's financial instruments by category. Fair values of financial instruments shown do not vary significantly from the balances shown in the Company and Consolidated statements of financial position.

| | Company | | | | | |
|---|---|---|---|---|---|---|
| | 9/30/2013 | | | 12/31/2012 | | |
| Description | Fair value through profit or loss | Loans and receivables | Amortized cost | Fair value through profit or loss | Loans and receivables | Amortized cost |
| Cash and cash equivalents and Marketable securities | **190,173** | **-** | **-** | 199,349 | - | - |
| Judicial deposits | **91,981** | **-** | **-** | 91,117 | - | - |
| Trade accounts receivable | **-** | **410,201** | **-** | - | 354,812 | - |
| **Assets** | **282,154** | **410,201** | **-** | 290,466 | 354,812 | - |
| Trade accounts payable | **-** | **-** | **52,789** | - | - | 54,714 |
| Bank loans and financing | **-** | **-** | **15,231** | - | - | 28,152 |
| Debentures | **-** | **-** | **984,142** | - | - | 958,984 |
| Derivatives | **163** | **-** | **-** | 1,233 | - | - |
| Taxes in installments | **-** | **-** | **10,566** | - | - | 12,392 |
| Payables for acquisition of subsidiaries | **-** | **-** | **38,135** | - | - | 58,600 |
| **Liabilities** | **163** | **-** | **1,100,863** | 1,233 | - | 1,112,842 |

| | Consolidated | | | | | |
|---|---|---|---|---|---|---|
| | 9/30/2013 | | | 12/31/2012 | | |
| Description | Fair value through profit or loss | Loans and receivables | Amortized cost | Fair value through profit or loss | Loans and receivables | Amortized cost |
| Cash and cash equivalents and Marketable securities | **291,514** | **-** | **-** | 318,107 | - | - |
| Judicial deposits | **96,751** | **-** | **-** | 95,274 | - | - |
| Trade accounts receivable | **-** | **592,556** | **-** | - | 498,455 | - |
| Assets | **388,265** | **592,556** | **-** | 413,381 | 498,455 | - |
| Trade accounts payable | **-** | **-** | **78,562** | - | - | 84,429 |
| Bank loans and financing | **-** | **-** | **124,991** | - | - | 147,397 |
| Debentures | **-** | **-** | **984,142** | - | - | 958,984 |
| Derivatives | **163** | **-** | **-** | 1,233 | - | - |
| Taxes in installments | **-** | **-** | **28,306** | - | - | 32,830 |
| Payables for acquisition of subsidiaries | **-** | **-** | **49,541** | - | - | 69,432 |
| **Liabilities** | **163** | **-** | **1,265,542** | 1,233 | - | 1,293,072 |

Fair value hierarchy

The Company holds only financial instruments qualified at level 2, corresponding to marketable securities in the consolidated amounts of R$ 259,233 at September 30, 2013 (R$ 302,020 at December 31, 2012) and derivatives in the consolidated amounts of R$ 163 at September 30, 2013 (R$ 1,233 at December 31, 2012).

## Notes to the quarterly information

The different levels are defined as follows:

- Level 1 - Prices (not adjusted) quoted in active markets for identical assets and liabilities.
- Level 2 - Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices).
- Level 3 - Assumptions for the asset or liability that are not based on observable market data (unobservable inputs).

a) *Estimated fair values*

Estimated fair value for financial instruments was developed using a pricing model applied individually to each transaction, taking into account future payment flows based on contractual terms, discounted to present value at rates obtained through the market interest curve, based on information obtained from the BM&FBovespa and ANBIMA websites.

Therefore a security's fair value corresponds to its value at maturity (redemption value) brought to present value using a discount factor (related to the maturity date) obtained from the market interest curve in Reais.

b) *Derivatives*

The hedge instruments contracted by the Company are non-deliverable forwards and interest rate swaps with no leverage component, margin call clause, daily adjustment or periodic adjustments. The assumptions used for calculation of assets and liabilities are broken down in the table below:

At September 30, 2013, the Company held the following swap operations:

*Financial instruments - derivatives payable (Consolidated)*

| | | | | | Fair value (Accounting) | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Company strategy** | **Index rate - assets** | **Assets** | **Index rate - liabilities** | **Liabilities** | **Fair value** | **Amounts** | **Gain (loss) in mark to market** | **Currency/ index** | **Maturity** | **Notional value** | **Market** | **Counterparty** |
| **Derivatives for debts hedge not assigned at fair value** | | | | | | | | | | | | |
| Swap - Hedge exchange rate | Dollar | 10,304 | 78.55% of CDI | (10,467) | (163) | (799) | 636 | Dollar | 04/2010 to 03/2016* | 4,669 | OTC | HSBC |
| | | 10,304 | | (10,467) | (163) | (799) | 636 | | | | | |
| Classified in current liabilities | | | | | (126) | | | | | | | |
| Classified in noncurrent liabilities | | | | | (37) | | | | | | | |

* Monthly maturity

The Company recognized gains and losses on its derivative instruments. However, since they are hedging derivatives, these gains and losses minimized the impact of exchange-rate and interest-rate variation incurred by the indebtedness that the derivatives were hedging. At September 30, 2013, derivative instruments had the following impacts on consolidated income:

| Derivatives | Risk | Account | Income (expenses) 9/30/13 | Income (expenses) 9/30/12 |
|---|---|---|---|---|
| HSBC (SWAP) | Exchange variation -Interest - fair value adjustment | Financial income/ (financial expenses) | **(706)** | (761) |
| | | | **(706)** | (761) |

*Sensitivity analysis of derivatives*

The Company carried out the sensitivity analysis for the main risks to which its financial instruments (including derivatives) are exposed, which basically refer to risks related to exchange and interest rate variations, as follows:

*Exchange-rate variation*

Fair value was calculated in accordance with projections made on the date of this quarterly financial information for future quotations of the US dollar obtained from BM&FBovespa. In the case of the scenarios, as determined by the abovementioned instruction, the stress percentages defined therein were added.

Assuming the notional exposure of quarterly financial information indexed to variable interest rates above are maintained, the effects of dollar depreciation on the Company's consolidated quarterly financial information, by type of financial instrument, for the two different scenarios, would be as follows:

| Contracts | Risk | Exposure | Fair value at 9/30/2013 | Depreciation 25% | Depreciation 50% |
|---|---|---|---|---|---|
| SWAP Contract – HSBC Long position – Exchange variation | Dollar drop - US$ | 4,669 | 10,304 | (2,576) | (5,152) |
| | | 4,669 | 10,304 | (2,576) | (5,152) |

*Interest-rate variation*

Market value was calculated in accordance with the projections on the date of this quarterly financial information for future quotations for each maturity date of principal and interest obtained on the BM&FBovespa. In the case of the scenarios, as determined by the abovementioned instruction, the stress percentages defined therein were added.

## Notes to the quarterly information

Assuming the exposure of financial instruments indexed to variable interest rates at September 30, 2013 is maintained, the effects of a higher interbank (CDI) on the Company's consolidated quarterly financial information, by type of financial instrument, for two different scenarios, would be as follows:

| Contracts | Risk | Exposure | Fair value at 9/30/2013 | Increase 25% | Increase 50% |
|---|---|---|---|---|---|
| SWAP Contract- HSBC Short position - Interest | CDI Increase | 4,669 | (10,467) | 32 | 63 |
| | | 4,669 | (10,467) | 32 | 63 |

Sensitivity analysis of financial assets and liabilities

The principal risks concerning the Company's operations relate to interbank (CDI) rate variations for promissory notes, debentures and marketable securities linked to the dollar exchange rate variation for senior notes and marketable securities.

CDI Investments are recorded at fair value, in accordance with quotations disclosed by the corresponding financial institutions and the others refer mostly to banking deposit certificates and repurchase agreements, therefore the amount recorded for these securities shows no difference in relation to fair value.

Based on expectations stated in the FOCUS/Bacen report, a projection for the next 12 months was obtained, with an average of 9.75% for CDI and R$ 2.37 for the exchange rate (R$/US$).

In order to verify the sensitivity of the index on marketable securities held by the Company at September 30, 2013, three different scenarios were defined, based on the projection and, from then on, the variations of 25% and 50% were calculated.

For each scenario gross financial expense / (income) was calculated, not including the impact of taxes and the flow of maturities of each contract scheduled for 2012.

| Transaction | Balance at September 30, 2013 | Risk | Scenario I (Probable) | Scenario II | Scenario III |
|---|---|---|---|---|---|
| Marketable securities | **29,675** | Dollar | 665 | 7,419 | 14,832 |
| Rate subject to variation | | | 2.18 | 1.67 | 1.12 |
| Marketable securities | **190,479** | CDI | 15,886 | 11,914 | 7,943 |
| Rate subject to variation | | | 8.34% | 6.26% | 4.17% |

In order to verify the sensitivity of our debts index at September 30, 2013, three different scenarios were defined based on the projection, from which variations of 25% and 50% were calculated.

Gross financial expenses / (income) were calculated for each scenario, not including the impact of taxes and the flow of maturities of each contract scheduled for 2012.

Gross financial expense was calculated for each scenario, not taking into consideration the impact of taxes and the flow of maturities of each contract scheduled for 2012. The reporting date used for financing was September 30, 2013, and the indices were projected for one year and their sensitivity determined for each scenario.

## Notes to the quarterly information

| Transaction | Balance at September 30, 2013 | Risk (a) | Scenario I (Probable) | Scenario II | Scenario III |
|---|---|---|---|---|---|
| Debentures | **987,458** | CDI | 96,277 | 120,346 | 144,416 |
| | | | 9.75% | 12.19% | 14.63% |
| Working capital | **23,849** | CDI | 2,325 | 2,907 | 3,488 |
| | | | 9.75% | 12.19% | 14.63% |
| Senior notes | **67,003** | Dollar | 4,206 | 16,751 | 33,502 |
| | | | 2.37 | 2.79 | 3.35 |

**(a)** Rate subject to variation

Fair value

| | Company | | | |
|---|---|---|---|---|
| | 9/30/2013 | | 12/31/2012 | |
| | Book value | Fair value | Book value | Fair value |
| **Assets** | | | | |
| Marketable securities | **182,191** | **182,191** | 186,680 | 186,680 |
| Judicial deposits | **91,980** | **91,980** | 91,117 | 91,117 |
| Trade accounts receivable | **410,201** | **410,201** | 354,812 | 354,812 |
| **Liabilities** | | | | |
| Trade accounts payable | **52,789** | **52,789** | 54,714 | 54,714 |
| Debentures | **984,142** | **992,112** | 958,984 | 962,649 |
| Derivatives | **163** | **163** | 1,233 | 1,233 |
| Loans and financing: | | | | |
| Other bank loans | **15,231** | **15,231** | 28,152 | 28,152 |

| | Consolidated | | | |
|---|---|---|---|---|
| | 9/30/2013 | | 12/31/12 | |
| | Book value | Fair value | Book value | Fair value |
| **Assets** | | | | |
| Marketable securities | **259,233** | **259,233** | 302,020 | 302,020 |
| Judicial deposits | **96,751** | **96,751** | 95,347 | 95,347 |
| Trade accounts receivable | **592,556** | **592,556** | 498,455 | 498,455 |
| **Liabilities** | | | | |
| Trade accounts payable | **78,562** | **78,562** | 84,429 | 84,429 |
| Debentures | **984,142** | **992,112** | 958,984 | 962,649 |
| Derivatives | **163** | **163** | 1,233 | 1,233 |
| Loans and financing: | | | | |
| Bank loan - Banco do Brasil | **23,851** | **23,851** | 28,669 | 28,753 |
| Senior notes | **-** | **-** | 59,652 | 64,020 |
| Other bank loans | **101,140** | **101,140** | 59,076 | 59,076 |
| | **124,991** | **124,991** | 147,397 | 151,849 |

## Notes to the quarterly information

## 27. Related parties

In the periods ended September 30, 2013 and 2012, the Company entered into transactions with related parties within its normal operating context, as shown below:

a) Transactions related to services rendered between Company and related parties

| Balance at end of period | 9/30/2013 | 12/31/2012 |
|---|---|---|
| **Current assets – Customers** | | |
| CientificaLab | **471** | 3,396 |
| CERPE | **82** | 162 |
| Cytolab | **-** | 6 |
| Previlab | **68** | 979 |
| | **621** | 4,543 |
| **Current liabilities – Other accounts payable** | | |
| DASA RE (i) | **71** | 184 |
| Sérgio Franco (ii) | **2,181** | 2,242 |
| | **2,252** | 2,426 |

| Income for the period | 9/30/2013 | 9/30/2012 |
|---|---|---|
| **Service revenue** | | |
| CientificaLab | **1,700** | 861 |
| CERPE | **581** | 473 |
| Previlab | **714** | 1.088 |
| Cytolab | **-** | 754 |
| | **2,995** | 3,176 |
| **Cost of services provided** | | |
| DASA RE (i) | **989** | 1,345 |
| CientificaLab (ii) | **-** | 99 |
| Sérgio Franco (ii) | **17,620** | 14,901 |
| | **18,609** | 16,345 |

(i) Amounts corresponding to property rent.

(ii) Amounts corresponding to clinical analysis services.

Transactions with related parties, as shown above, are carried out at cost and eliminated in the consolidated quarterly financial information.

b) Advances for future capital contribution (AFAC)

| | 09/30/13 | 31/12/12 |
|---|---|---|
| CientificaLab Produtos Laboratoriais e Sistemas Ltda. | **10,000** | 15,500 |

## Notes to the quarterly information

c) Management compensation

The total management compensation, including fixed compensation and bonuses totaled remuneration R$2,006 for the nine-month period ended September 30, 2013 and R$2,239 for the nine-month period ended September 30, 2012 paid to the Board of Directors' members (with five members in the nine-month period ended September 30, 2013 and also five members in 2012), and R$7,046 for the nine-month period ended September 30, 2013 and R$6,846 for the nine-month period ended September 30, 2012 paid to statutory members (nine statutory members in the nine-month period ended September 30, 2013 and average of 12 in the same period of 2012).

Share-based payment is disclosed in Note 22 (a). There are no additional benefits to the Company's key management members.

d) Balances of contracts between subsidiaries at September 30, 2013. These balances are not shown in the quarterly financial information since they do involve the parent Company and are eliminated in the consolidated statements.

| Lender | Borrower | 9/30/2013 | 12/31/2012 | Maturity date | Rate |
|---|---|---|---|---|---|
| Pro Echo | Sérgio Franco | **35,671** | 33,772 | 10/25/2016 | 100% CDI |
| Pro Echo | CDPI | **35,480** | 22,502 | 11/7/2017 | 100% CDI |
| Pro Echo | Check-Up | **3,951** | 2,829 | 12/17/2017 | CDI + 1.6% p.a. |
| Pro Echo | Previlab | **6,293** | 5,392 | 9/23/2017 | CDI + 1.6% p.a. |
| Pro Echo | CientificaLab | **7,441** | 7,045 | 11/8/2017 | 100% CDI |
| Pro Echo | Multi-Imagem | **2,246** | 2,127 | 5/30/2017 | 100% CDI |
| Pro Echo | CERPE | **-** | 614 | 12/26/2017 | 100% CDI |
| | | **91,082** | 74,281 | | |

*Transactions between the Company and other related parties*

*Link Consultoria em Medicina Diagnóstica Ltda:* an entity held by Alcione Moya Aprilante, shareholder of Previlab Análises Clínicas Ltda., which is a Company controlled by the DASA. It provides advisory services regionally in the management of health companies, and has market know-how, relationship with physicians practicing in the region where Previlab operates, as well as recognition by potential health professionals and customers.

*Medparts Participações e Negócios Ltda.:* entity held by Doctor Luciano Flávio Freitas de Almeida, member of Instituto de Endocrinologia e Medicina Nuclear do Recife Ltda. – CERPE, which renders services to the Company, providing advisory services on business management of medical companies, with market know-how, relationship with local physicians, and recognition of potential professionals and customers in healthcare field.

*Melania Angelieri Cunha Aprilante:* spouse of Doctor Alcione Moya Aprilante, shareholder of Previlab Análises Clínicas Ltda., owner of properties leased by Previlab, which is an entity controlled by the Company, located at:

| | | |
|---|---|---|
| Rua. Alferes José Caetano, nº 563 | Piracicaba | SP |
| Rua 15 de novembro, nº 1120 | Capivari | SP |
| Rua Presidente Roosevelt, nº 755 | Limeira | SP |
| Av. Brasil, nº 499 | Americana | SP |
| Rua Acácio do Canto, nº 189 | Piracicaba | SP |
| Rua Maceió, nº 242 | Piracicaba | SP |
| Rua Floriano Peixoto, nº 940 | São Pedro | SP |

## Notes to the quarterly information

_César Antonio Biazio Sanches:_ shareholder of Análises Clínicas Ltda., owner of the property leased by Previlab, which is an entity controlled by the Company, located at Rua Alferes Franco, nº 408 – Limeira, SP.

_A e C Consultores Ltda:_ an entity held by Cezar Antonio Biázio Sanches, shareholder of Previlab Análises Clínicas Ltda., which is a Company controlled by DASA. It provides business advisory and support services in the Previlab business area, as well as advisory, coaching, training and assessment of Previlab's employees and service providers.

_Pesmed – Pesquisas e Serviços Médicos Ltda:_ a Company controlled by Mr. Emerson Leandro Gasparetto, our radiology and graphical methods officer (elected March 26, 2012) and his wife, also a medical professional, Dr. Taisa Pallu Davaus Gasparetto, for consulting services in the form of medical research and surveys for subsidiaries: CDPI – Clínica de Diagnósticos por Imagem Ltda, CRMI – Clínica de Ressonância e Multi Imagem Ltda. The amounts are calculated based on the number of reports actually prepared by Pesmed, with due regard for the amount corresponding to each type of report, as per the list prepared by Company, using the same system adopted for the other providers of services for the Company..

_Lockall da Informática e Suprimentos Ltda – ME:_ A Company owned by the spouse of Claudia Cohn, who is an executive officer of Alta, with is the company in charge of installing cable TV outlets in the Company's business units.

_RMR Ressonância Magnética Ltda:_ a Company with shareholders jointly holding 33.24% of its capital who are the brothers of Mr. Romeu Cortês Domingues, chairman of the board of directors of the Company (elected April 26, 2011) , which provides medical services in the field of magnetic resonance imaging for these subsidiaries: CDPI – Clínica de Diagnósticos por Imagem Ltda; CRMI – Clínica de Ressonância e Multi Imagem Ltda; and Clínica de Ressonância e Multi-Imagem Caxias Ltda. Amounts are calculated based on revenue from magnetic resonance imaging services and numbers of exams produced by RMR, recognizing the corresponding charge for each type of report, as per the list prepared by the Company and using the same system adopted for the other providers of services for the Company.

_Ultrascan Serviços de Imagem Ltda:_ Company owned by Eduardo Luiz Primo de Siqueira, who holds 7.5% of Clinica de Ressonância Multi-Imagem Petrópolis Ltda, which provides medical services in the imaging area for the controlled Company Clinica de Ressonância Multi-Imagem Petropolis Ltda. The amounts are calculated based on the imaging service revenue and the number of reports prepared by Ultrascan, subject to the amount corresponding to each report type, according to the subsidiary's table, and they should further comply with the same system adopted for the other service providers of subsidiary.

_DMG Laboratório Médico Ltda:_ a franchise of the controlled Company Laboratórios Médicos Dr. Sérgio Franco Ltda., whose managing partner is Neusa de Godoy Bueno Joaquim, mother-in-law of the regional chief financial officer of the controlled Company Laboratórios Médicos Dr. Sérgio Franco Ltda., Carlos Fabio Ferreira Xavier. The franchise commission is calculated based on DMG's service revenue, subject to the same system adopted for the other franchisees.

_Lâmina Laboratório de Patologia Prevenção de Câncer Ltda:_ an entity whose partner is Adilia Jane de Alcantara Segura, non-statutory medical officer of the Company, for clinical pathology services. The amounts are calculated based on the number of examinations effectively made by Lâmina, subject to the amount corresponding to each examination type, according to the Company table and pursuant to the same system adopted for the other services providers.

## Notes to the quarterly information

Following are the amounts corresponding to services provided by the companies above for the periods ended September 30, 2013 and 2012:

| Contractor | Contracting party | 9/30/2013 | 9/30/2012 |
|---|---|---|---|
| Link Consultoria em Medicina Diagnóstica Ltda: | Previlab | **143** | 94 |
| A e C Consultoria Ltda. | Previlab | **302** | 290 |
| Pesmed – Pesquisa e Serviços Médicos Ltda. | CDPI | **212** | 224 |
| Pesmed – Pesquisa e Serviços Médicos Ltda. | CRMI | **69** | 69 |
| RMR Ressonância Magnética Ltda. | CDPI | **1298** | 1378 |
| RMR Ressonância Magnética Ltda. | CRMI | **1355** | 1333 |
| RMR Ressonância Magnética Ltda. | CRMI Caxias | **65** | 56 |
| Medparts Participações e Negócios Ltda. | DASA | **187** | - |
| Melania Angelieri Cunha Aprilante | Previlab | **182** | 140 |
| César Antonio Biazio Sanches | Previlab | **63** | 42 |
| Lockall da Informática e Suprimentos Ltda – ME | DASA | **35** | 8 |
| DMG Laboratório Médico Ltda. | Sergio Franco | **739** | 672 |
| Ultrascan Serviços de Imagem Ltda. | CRMI Petrópolis | **154** | 53 |
| Laboratórios de Pat. Prev. Câncer Ltda. | DASA | **187** | 128 |

## 28. Financial and operating lease

Local currency leases

The Company is a lessee of assets recorded in property and equipment, with purchase options, for which the balance payable until 2015 amounts to R$ 19.148, consolidated, R$ 13,157 of which under current liabilities and R$ 5.991 under noncurrent liabilities. The average term of the contracts is 36 months and they bear interest rates varying from CDI + 1.53 % p.a. to CDI + 2.00 % p.a.

Future minimum payments under loans and financing (see Note 16) are segregated as follows:

| | 9/30/13 | | | | | |
|---|---|---|---|---|---|---|
| | Company | | | Consolidated | | |
| | Present value of minimum lease payments | Interest | Future minimum payments | Present value of minimum lease payments | Interest | Future minimum payments |
| Up to one year | **3,528** | **95** | **3,623** | **13,157** | **353** | **13,510** |
| One to five years | **1,768** | **47** | **1,815** | **5,991** | **160** | **6,151** |
| | **5,296** | **142** | **5,438** | **19,148** | **513** | **19,661** |

| | 12/31/2012 | | | | | |
|---|---|---|---|---|---|---|
| | Company | | | Consolidated | | |
| | Present value of minimum lease payments | Interest | Future minimum payments | Present value of minimum lease payments | Interest | Future minimum payments |
| Up to one year | 4,205 | 176 | 4,381 | 15,632 | 653 | 16,285 |
| One to five years | 4,041 | 169 | 4,210 | 15,169 | 634 | 15,803 |
| | 8,246 | 345 | 8,591 | 30,801 | 1,287 | 32,088 |

## Notes to the quarterly information

The assets listed below are included in the property and equipment for the Company and its subsidiaries.

Net book values of assets acquired through local financial leases are:

| | Company | | Consolidated | |
|---|---|---|---|---|
| | **9/30/2013** | **12/31/2012** | **9/30/2013** | **12/31/2012** |
| Machinery and equipment | **6,359** | 7,560 | **18,035** | 20,391 |
| Furniture and fixtures | **38** | 48 | **51** | 62 |
| Vehicles | **-** | 1 | **30** | 42 |
| IT equipment | **408** | 694 | **600** | 1,052 |
| Facilities | **61** | 70 | **61** | 68 |
| IT system | **2** | 3 | **17** | 30 |
| | **6,868** | 8,376 | **18,794** | 21,645 |

Foreign currency leases

The Company leases equipment used to provide services, in accordance with lease agreements with purchase options. The payment term is 84 months, and a grace period of six months was granted for the first installment payment, and the remaining installments are to be paid on a quarterly and semi-annual basis. The quarterly and semi-annual installments in U.S. dollars are translated into reais at the market exchange rate effective on the payment date, plus interest from 7.20% per annum to 8.35% per annum, the balance payable totaling R$ 11,762 by 2016, R$ 8,621 thereof being recorded under current liabilities and R$ 3.141 under noncurrent liabilities.

Future minimum payments are segregated as follows:

| | 9/30/02013 | | | | | |
|---|---|---|---|---|---|---|
| | Company | | | Consolidated | | |
| | **Present value of minimum lease payments** | **Interest** | **Future minimum payments** | **Present value of minimum lease payments** | **Interest** | **Minimum future payments** |
| Up to one year | **7,411** | **455** | **7,866** | **8,621** | **529** | **9,150** |
| One to five years | **2,524** | **155** | **2,679** | **3,141** | **193** | **3,334** |
| | **9,935** | **610** | **10,545** | **11,762** | **722** | **12,484** |

| | 12/31/2012 | | | | | |
|---|---|---|---|---|---|---|
| | Company | | | Consolidated | | |
| | **Present value of minimum lease payments** | **Interest** | **Future minimum payments** | **Present value of minimum lease payments** | **Interest** | **Minimum future payments** |
| Up to one year | 11,384 | 747 | 12,131 | 12,984 | 852 | 13,836 |
| One to five years | 7,271 | 477 | 7,748 | 8,403 | 552 | 8,955 |
| | 18,655 | 1,224 | 19,879 | 21,387 | 1,404 | 22,791 |

The international finance lease agreements are included in property and equipment as machinery and equipment, totaling R$ 44,851 (R$ 53,800 at December 31, 2012) - Company and R$ 60,481 (R$ 72,507 at December 31, 2012) – consolidated.

## Notes to the quarterly information

Operating lease

Future minimum property rent payable on operating leases not subject to cancellation in consolidated are the following:

| | 9/30/2013 | | | 12/31/2012 | | |
|---|---|---|---|---|---|---|
| | Fixed-income agreements | Variable income agreements | Total | Fixed-income agreements | Variable income agreements | Total |
| Within one year | 111,045 | 5,838 | 116,883 | 105,718 | 2,228 | 107,946 |
| More than one year, but less than five years | 200,190 | 10,524 | 210,714 | 232,463 | 4,884 | 237,347 |
| More than five years | 113,089 | 570 | 113,659 | 87,367 | 2,515 | 89,882 |
| | 424,324 | 16,932 | 441,256 | 425,548 | 9,627 | 435,175 |

## 29. Net revenue

The following table shows reconciliation between gross revenue for tax purposes and revenue shown in the statement of income for the period:

| | Company | | Consolidated | |
|---|---|---|---|---|
| | **9/30/2013** | **9/30/2012** | **9/30/2013** | **9/30/2012** |
| Gross revenue | **1,471,693** | 1,339,473 | **2,055,677** | 1,885,727 |
| Deductions: | | | | |
| Taxes | **(83,522)** | (75,919) | **(115,102)** | (108,245) |
| Provision for and losses due to disallowance and default | **(52,198)** | (49,363) | **(76,111)** | (55,149) |
| Discounts | **(5,099)** | (5,522) | **(5,373)** | (5,591) |
| | **1,330,874** | 1,208,669 | **1,859,091** | 1,716,742 |

## 30. Financial income

| | Company | | Consolidated | |
|---|---|---|---|---|
| | **9/30/2013** | **9/30/2012** | **9/30/2013** | **9/30/2012** |
| **Financial expenses** | | | | |
| Interest | **(101,029)** | (76,910) | **(117,203)** | (92.736) |
| Monetary and exchange variation losses | **(5,790)** | (13,920) | **(10,662)** | (19.371) |
| Other | **(9,826)** | (17,978) | **(13,197)** | (21.724) |
| | **(116,645)** | (108,808) | **(141,062)** | (133.831) |
| **Financial income** | | | | |
| Interest | **16,226** | 10,810 | **21,959** | 24.273 |
| Monetary and exchange variation losses | **5,982** | 13,960 | **7,654** | 16.646 |
| Other **(a)** | **43,875** | 884 | **45,008** | 1.367 |
| | **66,083** | 25,654 | **74,621** | 42.286 |
| | **(50,562)** | (83,154) | **(66,441)** | (91.545) |

**(a)** The gain obtained by joining PEP/SP in the amount of R$ 12,012 (see Note 21), is represented by the amount of R$ 31,224, recorded under Interest and by the amount of R$ 43,236, recorded under Other.

## 31. Subsequent events

4th Issue of Debentures

On September 13, 2013, the Company's Board of Directors approved the forth issuance of up to 45,000 unsecured debentures in a single series not convertible into shares, with par value of R$10,000.00, totaling R$450,000 for public distribution with restrict placement efforts under CVM Ruling No. 476, of January 16, 2009, including the amendments thereto.

On October 18, 2013, the Company communicated its shareholders and the market in general the ending on October 17, 2013 of the Public Distribution with Restrict Placement Efforts of the Company's forth issue in a single series of unsecured debentures not convertible into shares. A total of 45,000 Debentures were subscribed, with a five-year term as from the issue date totaling R$ 450,000. The debentures will not be subject to monetary restatement and the debt balance of the nominal value of each Debenture will be subject to interest corresponding to 100% of the accumulated variation of daily average rates of One-day Interbank Deposits, “over extra-group”, expressed as percentage per year, based on 252 working days, calculated and published by CETIP, increased by a surcharge of 1.15% p.a., based on 252 working days, calculated exponentially and cumulative on a pro rata temporis by working days elapsed as from the payment date, or the payment date of compensation immediately before that date, as the case may be, until the effective payment date.

The compensation shall be paid on a half-yearly basis as from the issue date, being the first payment due on April 15, 2014 and the last on the maturity date, without impact on the payments due to early redemption of Debentures, of early amortization of Debentures and/or of early maturity of obligations arising from the Debentures.

The amortization of the principal will take place in two annual installments, in 48th 60th month, as from the issue date of debentures.

The financial settlement of the offer took place on October 16, 2013 amounting to R$450,000 and net funds of the offer were used to strengthen working capital and refinance debts.

The debentures have clauses determining maximum indebtedness and leverage levels, which are calculated according to (i) net debt / EBITDA, which should be lower than or equal to 3.0, and (ii) EBITDA/ financial income, which should be higher than or equal to 2.0.

## Shareholding structure

Controlling shareholders, managing officers and outstanding shares

### Position at September 30, 2013

| Shareholders | Common shares (unit) | % | Total shares (unit) | % |
|---|---|---|---|---|
| **Board of directors** | **7,470,953** | **2.40%** | **7,470,953** | **2.40%** |
| **Staff of officers** | **69,866** | **0.02%** | **69,866** | **0.02%** |
| **Statutory Audit Committee** | **1** | **0.00%** | **1** | **0.00%** |
| **Treasury stock** | **1,159,035** | **0.37%** | **1,159,035** | **0.37%** |
| **Outstanding shares** | **303,103,160** | **97.21%** | **303,103,160** | **97.21%** |
| Total shares | 311,803,015 | 100.00% | 311,803,015 | 100.00% |

At September 30, 2013, the Company did not have a Supervisory Board.

### Position at September 30, 2012

| Shareholders | Common shares (unit) | % | Total shares (unit) | % |
|---|---|---|---|---|
| **Board of directors** | **7,470,957** | **2.40%** | **7,470,957** | **2.40%** |
| **Staff of officers** | **49,310** | **0.01%** | **49,310** | **0.01%** |
| **Treasury stock** | **1,159,035** | **0.37%** | **1,159,035** | **0.37%** |
| **Outstanding shares** | **303,123,713** | **97.22%** | **303,123,713** | **97.22%** |
| Total shares | 311,803,015 | 100.00% | 311,803,015 | 100.00% |

At September 30, 2012, the Company did not have a Supervisory Board.

### Arbitration clause

The Company is bound to arbitration by the Market Arbitration Chamber, pursuant to the arbitration clause provided for in its articles of incorporation.

## Independent auditor's review report on quarterly financial information

The Board of Directors, Shareholders and Officers
**Diagnósticos da América S.A.**

### Introduction

We have reviewed the accompanying individual and consolidated interim financial information contained in the Quarterly Information Form (ITR) of Diagnósticos da América S.A. ("Company") and subsidiaries for the quarter ended September 30, 2013, comprising the balance sheet as at September 30, 2013 the related income statement and comprehensive income statement for the three and nine-month periods then ended, and the statement of changes in equity and cash flows statement for the nine-month period then ended, including the explanatory notes.

Management is responsible for the preparation of the individual interim financial information in accordance with CPC 21 (R1) - Interim Financial Reporting, and consolidated interim financial information in accordance with CPC 21 (R1) and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the fair presentation of this information in conformity with the standards issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

### Scope of review

We conducted our review in accordance with Brazilian and International Standards on Review Engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion on the individual interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the individual interim financial information included in the quarterly financial information referred to above is not prepared, in all material respects, in accordance with CPC 21 (R1) applicable to the preparation of the Quarterly Information (ITR), and presented consistently with the standards issued by the Brazilian Securities and Exchange Commission (CVM).

### Conclusion on the consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the consolidated interim financial information included in the quarterly financial information referred to above is not prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34 applicable to the preparation of the Quarterly Information (ITR), and presented consistently with the standards issued by the Brazilian Securities and Exchange Commission (CVM).

### Other matters

### Statements of value added

We also reviewed the individual and consolidated statements of value added (SVA), for the nine-month period ended September 30, 2013, prepared under the responsibility of Company management, whose presentation in the interim financial information is required by the standards issued by the Brazilian Securities and Exchange Commission (CVM) applicable to preparation of Quarterly Information (ITR) and considered supplementary information under IFRS, which do not require SVA presentation. These statements were submitted to the same review procedures previously described and, based on our review, nothing has come to our attention that would make us believe that they were not prepared, in all material respects, consistent with the overall individual and consolidated interim financial information.

São Paulo, November 11, 2013.

ERNST & YOUNG TERCO
Auditores Independentes S.S.
CRC-2SP015199/O-6

Antonio Carlos Fioravante
Accountant CRC-1SP184973/O-0

## Opinions and Statements / Statement of Officers on the Financial Statements

Observing the provision of article 25 of Ruling No. 480/09 of December 7, 2009, the Board represents that it has reviewed, discussed and agreed with the Quarterly information (Company and Consolidated) for period ended September 30, 2013.

Barueri, September 11, 2013.

CEO - Dickson Esteves Tangerino

Investor Relations Officer - Paulo Bokel Catta-Preta

CFO – Paulo Bokel Catta-Preta

Chief Accounting Officer and Infrastructure - Carlos Elder Maciel de Aquino

## Opinions and Declarations / Statement of Officers on the Independent Auditors Report

In compliance with the provisions of article 25, Instruction # 480/09, of December 7, 2009, the Staff of Officers represents that it has reviewed, discussed and agreed with the opinion expressed in the Independent Auditors' Opinion, dated September 11, 2013, related to the quarterly information (Company and Consolidated) for the period ended on September 30, 2013.

Barueri, September 11, 2013.

CEO - Dickson Esteves Tangerino

Investor Relations Officer - Paulo Bokel Catta-Preta

CFO - Paulo Bokel Catta-Preta

Chief Accounting Officer and Infrastructure - Carlos Elder Maciel de Aquino